{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.17418"}, {"@name": "filename", "#text": "24208_Petroli_ReginaldoJose_D.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "i \n \n\n \n\n \n\nREGINALDO JOS\u00c9 PETROLI \n\n \n\n \n\n \n\n \n\n \n\n\u201cEFFECT OF NOVEL MUTATIONS IN ANDROGEN RECEPTOR UPON MOLECULAR \n\nMECHANISMS\u201d \n\n \n\n \n\n \n\n\u201cEFEITOS DE NOVAS MUTA\u00c7\u00d5ES NO RECEPTOR DE ANDR\u00d3GENOS SOBRE OS \n\nMECANISMOS MOLECULARES\u201d \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAMPINAS \n\n2014 \n\n\n\nii \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\niii \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\niv \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nv \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nvi \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nvii \n \n\nABSTRACT \n\nThe androgen receptor (AR) is a transcription factor that belongs to the superfamily of \n\nnuclear receptors activated by phosphorylation and dimerization by hormone binding. \n\nSeveral functions are attributed for AR, like male sex development, regulation of gene \n\nexpression and cell differentiation in target tissues. The aim of this study was to analyze the \n\neffect of mutations p.Pro695Ser, p.Ser759Tre, p.Leu768Val, p.Cys806Phe+ p.Gln798Glu, \n\np.Leu830Phe, p.Ile898Phe and p.Pro904Arg upon AR transactivation activity. All \n\nmutations studied here are located in the hormone-binding domain and were identified in \n\npatients with different degrees of androgen insensitivity syndrome (AIS) by AR gene \n\nsequencing. Mutations in this domain can result in the impairment of androgen ligation, but \n\nthere are cases that it does not affect the binding but interfere with the interaction between \n\nthe amino and carboxi-terminal domains (N/C terminal), important step for receptor-\n\nbinding stabilization. Thus, both functions have been studied in this work. To evaluate the \n\nability of AR transactivation of mutant proteins, the site-directed mutagenesis assay was \n\nperformed on full-length cDNA, followed by transfection and expression in mammalian \n\ncells. The analysis of transactivation of a reporter gene with different dihydrotestosterone \n\n(DHT) concentrations was performed. The analysis of N/C-terminal interactions for each \n\nmutant AR was performed by two- hybrid mammalian assay. The mutation p.Pro695Ser \n\nreveled transactivation activities of 85% and 82% in transactivation assays with the full-\n\nlength cDNA and two hybrid assay, respectively, at DHT physiological values \n\n(approximately 1 nM). The activities reached normal values at high DHT concentrations, \n\nindicating a low effect on gonadal activity. However, in low DHT concentrations, the \n\ntransactivation activity decays to less than 50% in both experiments, which may affect AR \n\nfunctions in non-gonadal tissues. This mutation was considered \"mild\" and corresponds \n\nperfectly to the male phenotype of the patient who presented with gynecomastia, but with \n\npreserved fertility. With 1 nM hormone, the p.Ser759Tre, p.Leu830Phe, p.Ile898Phe \n\nmutations showed transactivation activity higher than 20%, the response increased with \n\nhigher DHT concentrations.  However, in N/C interaction assays, those mutations showed \n\ndifferent results. The p.Ile898Phe revealed a complete disruption in N/C interaction at all \n\nhormone concentrations; the p.Ser759Tre and p.Leu830Phe showed positive response with \n\nthe increasing in DHT concentrations and reached 50% and 250% of the transcriptional \n\n\n\nviii \n \n\nactivity of wild type, respectively. Such results indicate a partial AIS phenotype (PAIS) as \n\nfunctional effect for p.Ser759Tre and p.Leu830Phe. In these cases there was a positive \n\ncorrelation with the phenotypes of patients that presented different degrees of PAIS. For the \n\np.Ile898Phe, the expected phenotype based on functional analysis would be the complete \n\nform of AIS (CAIS), but the patients with this mutation had variable degrees of genital \n\nambiguity consistent to PAIS. This indicates that other factors must influence the \n\nphenotypic manifestation. The p.Leu768Val revealed a complete disruption at 1 nM DHT \n\nin both experiments, typical of CAIS. The p.Gln798Glu and p.Cys806Phe mutations \n\nstudied separately revealed responses to the induction of DHT similar to Mild and Partial \n\nphenotypes, respectively. However, when analyzed together, the transactivation activity of \n\n1 nM was lower than 10%, increasing in high ligand concentration, which is consistent to \n\nCAIS phenotype. Finally, p.Pro904Arg, although showed residual transcriptional activity \n\naround 20% of the wild type in the experiment with the full-length cDNA, it abolished the \n\ntranscriptional activity when N/C terminal interaction was tested indicating a CAIS \n\nphenotype, as observed in the patient. Functional analysis of the AR performed here could \n\nelucidate some molecular mechanisms associated with each mutation, and may provide a \n\nbasis for response to treatment with DHT in each particular case. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\nix \n \n\nRESUMO \n\nO receptor de andr\u00f3genos, do ingl\u00eas androgen receptor (AR) \u00e9 um fator de transcri\u00e7\u00e3o \n\npertencente \u00e0 superfam\u00edlia de receptores nucleares o qual \u00e9 ativado por fosforila\u00e7\u00e3o e \n\ndimeriza\u00e7\u00e3o sob a liga\u00e7\u00e3o ao horm\u00f4nio. V\u00e1rias fun\u00e7\u00f5es s\u00e3o atribu\u00eddas a este receptor, sendo \n\na principal delas o desenvolvimento e manuten\u00e7\u00e3o das caracter\u00edsticas sexuais masculinas, \n\natua na regula\u00e7\u00e3o da express\u00e3o g\u00eanica e diferencia\u00e7\u00e3o celular em tecidos alvos. O presente \n\ntrabalho teve por objetivo principal a an\u00e1lise do efeito das muta\u00e7\u00f5es p.Pro695Ser, \n\np.Ser759Tre, p.Leu768Val, p.Cis806Fen+p.Gln798Glu, p.Leu830Fen, p.Ile898Fen e \n\np.Pro904Arg sobre a fun\u00e7\u00e3o do AR. As muta\u00e7\u00f5es acima citadas, localizadas no dom\u00ednio de \n\nliga\u00e7\u00e3o ao horm\u00f4nio, foram identificadas por sequenciamento direto do gene do AR de \n\npacientes 46,XY com diferentes graus da S\u00edndrome da Insensibilidade Androg\u00eanica (AIS). \n\nMuta\u00e7\u00f5es nesse dom\u00ednio geralmente rompem a liga\u00e7\u00e3o aos andr\u00f3genos naturais, por\u00e9m h\u00e1 \n\nalgumas que n\u00e3o afetam essa liga\u00e7\u00e3o, mas interferem na intera\u00e7\u00e3o entre os dom\u00ednios amino \n\ne carboxi-terminal (N/C terminal), importante para a estabiliza\u00e7\u00e3o receptor-ligante. Assim, \n\nambas fun\u00e7\u00f5es foram investigadas. Para se avaliar a capacidade de transativa\u00e7\u00e3o das \n\nprote\u00ednas AR mutantes, foi realizada a t\u00e9cnica de mutag\u00eanese s\u00edtio dirigida no cDNA \n\ncompleto, seguida de transfec\u00e7\u00e3o e express\u00e3o em c\u00e9lulas de mam\u00edferos e an\u00e1lise de \n\ntransativa\u00e7\u00e3o induzida por concentra\u00e7\u00f5es crescentes de diidrotestosterona (DHT) \n\nutilizando-se um gene rep\u00f3rter. A an\u00e1lise das intera\u00e7\u00f5es N/C-terminal para cada AR \n\nmutante foi realizada pela t\u00e9cnica de duplo-h\u00edbrido em c\u00e9lulas de mam\u00edferos. A muta\u00e7\u00e3o \n\np.Pro695Ser apresentou atividades de transativa\u00e7\u00e3o de 85% e 82% nos ensaios \n\ntransativa\u00e7\u00e3o com o cDNA completo e no duplo-h\u00edbrido, respectivamente, em valores de \n\nDHT fisiol\u00f3gicos (cerca de 1 nM). As atividades atingiram valores normais em \n\nconcentra\u00e7\u00f5es elevadas de DHT indicando um baixo efeito sobre a atividade gonadal. No \n\nentanto, em concentra\u00e7\u00f5es de DHT inferiores a atividade de transativa\u00e7\u00e3o decai para menos \n\nde 50% nos dois experimentos, podendo afetar as fun\u00e7\u00f5es do AR em tecidos n\u00e3o gonadais. \n\nEsta muta\u00e7\u00e3o foi considerada \u201cbranda\u201d e corresponde perfeitamente ao fen\u00f3tipo masculino \n\ndo paciente que se apresentava com ginecomastia, mas com fertilidade preservada. Com 1 \n\nnM de horm\u00f4nio, as muta\u00e7\u00f5es p.Ser759Tre, p.Leu830Fen, p.Ile898Fen apresentaram \n\natividade de transativa\u00e7\u00e3o superior a 20%, havendo um aumento de resposta com \n\nconcentra\u00e7\u00f5es crescentes. No entanto, o comportamento de cada uma no experimento de \n\n\n\nx \n \n\nintera\u00e7\u00e3o N/C diferiu sendo que a p.Ile898Fen n\u00e3o apresentou atividade em nenhuma \n\nconcentra\u00e7\u00e3o de ligante; as p.Ser759Tre e p.Leu830Fen responderam positivamente ao \n\naumento da concentra\u00e7\u00e3o de DHT atingindo 50% e 250% da atividade transcricional do \n\nreceptor selvagem, respectivamente. Esses resultados indicam um fen\u00f3tipo parcial de AIS \n\n(PAIS) para os portadores das muta\u00e7\u00f5es p.Ser759Tre e p.Leu830Fen. Nesses casos \n\nverificou-se uma boa correla\u00e7\u00e3o dos achados funcionais com os fen\u00f3tipos dos pacientes que \n\napresentavam graus variados de PAIS. J\u00e1 para a muta\u00e7\u00e3o p.Ile898Fen o fen\u00f3tipo esperado \n\nbaseando-se nos resultados funcionais seria o de AIS na forma completa (CAIS), por\u00e9m os \n\npacientes portadores desta muta\u00e7\u00e3o apresentavam graus variados de ambiguidade genital \n\ncompat\u00edveis com o fen\u00f3tipo PAIS. Isto indica que outros fatores devem estar influenciando \n\na manifesta\u00e7\u00e3o fenot\u00edpica nesse caso. A muta\u00e7\u00e3o p.Leu768Val apresentou atividade \n\ntranscricional nula em 1 nM de DHT nos dois experimentos, um perfil t\u00edpico do fen\u00f3tipo \n\nCAIS apresentado pelo portador desta muta\u00e7\u00e3o. As muta\u00e7\u00f5es p.Gln798Glu e p.Cis806Fen \n\nestudadas separadamente apresentaram respostas \u00e0 indu\u00e7\u00e3o de DHT semelhantes \u00e0s de \n\nmuta\u00e7\u00f5es \u201cbrandas\u201d e PAIS, respectivamente. No entanto, quando estudadas em conjunto, a \n\natividade de transativa\u00e7\u00e3o com 1 nM foi inferior a 10%, aumentando com o aumento da \n\nconcentra\u00e7\u00e3o de ligante, comportamento compat\u00edvel com muta\u00e7\u00f5es mais graves resultando \n\nno fen\u00f3tipo CAIS observado nesse caso. Por \u00faltimo, a muta\u00e7\u00e3o p.Pro904Arg, embora tenha \n\nreduzido a atividade transcricional para cerca de 20% da selvagem no experimento com o \n\ncDNA completo, no experimento com duplo h\u00edbrido a atividade foi nula indicando uma \n\na\u00e7\u00e3o mais grave compat\u00edvel com a forma CAIS observada. A an\u00e1lise funcional do AR aqui \n\nrealizada pode elucidar alguns mecanismos moleculares associados a cada muta\u00e7\u00e3o, bem \n\ncomo pode fornecer subs\u00eddios para a resposta ao tratamento com DHT em cada caso em \n\nparticular.  \n\n \n\n \n\n \n\n \n\n\n\nxi \n \n\nSUM\u00c1RIO \n\n \n\nABSTRACT..........................................................................................................................vii \n\nRESUMO...............................................................................................................................ix \n\n \n\n1. INTRODU\u00c7\u00c3O..................................................................................................................1 \n\n1.1.Receptor de Andr\u00f3genos...................................................................................................1 \n\n1.2. A Prote\u00edna do Receptor de Andr\u00f3genos ..........................................................................3 \n\n1.2.1 Dom\u00ednio Regulador Transcricional................................................................................3 \n\n1.2.2 Dom\u00ednio de liga\u00e7\u00e3o ao DNA..........................................................................................5 \n\n1.2.3 Regi\u00e3o hinge ..................................................................................................................7 \n\n1.2.4 Dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio...................................................................................7 \n\n1.3 A\u00e7\u00e3o Androg\u00eanica ............................................................................................................8 \n\n1.4 Muta\u00e7\u00f5es no Gene AR.....................................................................................................10 \n\n1.5 A Insensibilidade Androg\u00eanica.......................................................................................11 \n\n1.5.1 Insensibilidade Completa aos Andr\u00f3genos..................................................................13 \n\n1.5.2 Insensibilidade Parcial aos Andr\u00f3genos.......................................................................14 \n\n1.5.3 Insensibilidade Branda aos Andr\u00f3genos......................................................................14 \n\n \n\n2. OBJETIVOS GERAIS......................................................................................................16 \n\n2.1 OBJETIVOS ESPEC\u00cdFICOS..........................................................................................17 \n\n \n\n3. Cap\u00edtulo 1 \u2013 Artigo:  Severe forms of partial androgen insensitivity syndrome due to \n\np.L830F novel mutation in androgen receptor gene in a Brazilian family\u2026\u2026\u2026\u2026..\u2026..18 \n\n \n\n4. Cap\u00edtulo 2 - Artigo: Functional analysis of six androgen receptor mutations identified in \n\npatients with complete and partial androgen insensitivity \n\nsyndrome\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026.\u2026..\u202625 \n\n \n\n5. Cap\u00edtulo 3 \u2013 Artigo: Functional studies for p.Pro695Ser androgen receptor mutation: \n\nassociation with gynecomastia and fertility\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u202652 \n\n\n\nxii \n \n\n \n\n6. DISCUSS\u00c3O.....................................................................................................................68 \n\n \n\n7. CONCLUS\u00d5ES ................................................................................................................72 \n\n8. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS .............................................................................73 \n\n \n\n9. ANEXOS...........................................................................................................................80 \n\n9.1ANEXO I: Localiza\u00e7\u00e3o prot\u00e9icas das muta\u00e7\u00f5es estudadas..............................................80 \n\n9.2ANEXO II: Declara\u00e7\u00e3o Bio\u00e9tica e Biosseguran\u00e7a...........................................................85 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nxiii \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nA MINHA ESPOSA PRISCILA  \n\nE AOS MEUS FILHOS VITOR E VIT\u00d3RIA, \n\nDEDICO. \n\n \n\n \n\n\n\nxiv \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nxv \n \n\nAGRADECIMENTOS  \n\nPrimeiramente, agrade\u00e7o a Deus que me deu for\u00e7a de vontade e determina\u00e7\u00e3o para encarar o desafio \n\nda realiza\u00e7\u00e3o deste trabalho. \n\n\u00c0 Professora Maricilda pela oportunidade e pela confian\u00e7a em meu trabalho. Agrade\u00e7o tamb\u00e9m \n\npelo apoio e pela amizade e principalmente pela porta que me abriu para o mundo cient\u00edfico.  \n\nAgrade\u00e7o aos meus pais: Jos\u00e9 Petroli e Maria Aparecida pelo exemplo de vida, de dignidade e pela \n\ndedica\u00e7\u00e3o que nunca faltou quando precisei. \u00c0 minha irm\u00e3 Regina, \u00e0 minha sobrinha Regiane e meu \n\ncunhado Marcos pelo apoio.  \n\n\u00c0 minha esposa Priscila pelo companheirismo e pelo amor que sempre esteve presente e que nos \n\nune. Pelo apoio fundamental e pela compreens\u00e3o nos momentos que mais precisei tanto perto \n\nquanto distante.  S\u00f3 assim, consegui terminar este trabalho.  \n\nAo meu sogro Jos\u00e9 Ant\u00f4nio e \u00e0 minha sogra Lucimar pelos conselhos e pela ajuda.  \n\nAos meus amigos Alan e Edilaine; Maicon, Fernanda e Isabella; Fernando e Gra\u00e7a, Gi e Vin\u00edcius; \n\nLeandro; Paulo e Jouze; Carol e Jeff; Silvana; Man\u00e9, V\u00e2nia e Vin\u00edcius; Ju, Neto, Gabi e Bia, pela \n\namizade e pelos momentos de descontra\u00e7\u00e3o!  \n\nA todos os amigos do laborat\u00f3rio de gen\u00e9tica molecular humana: Mara, Fl\u00e1via, D\u00e9bora, Cris, \n\nHelena, Dri, Emerson, a professora Edi, Sueli, Vanessa, Priscila, Carol, Nat\u00e1lia, Bruna, Paulo, \n\nmuito obrigado a todos pelos bons momentos, pelo companheirismo e pela amizade desenvolvida \n\nao longo destes anos.   \n\nAos professores, alunos e funcion\u00e1rios do CBMEG.  \n\nAos meus amigos alem\u00e3es: Olaf Hiort que permitiu a minha estada em seu laborat\u00f3rio. Ao Werner \n\npor todo o conhecimento cient\u00edfico e pelos descontra\u00eddos momentos na praia de Travemunde. \n\nForam momentos que certamente irei guardar por toda a vida. \u00c0 Bethina, Dagmar, Helga, Detlev e \n\nPia, sempre prontos a me ajudar. \n\n\u00c0 FAPESP, CAPES, CNPq e Euro DSD pelo apoio financeiro.  \n\n\u00c0 todas as fam\u00edlias que comp\u00f5e a casu\u00edstica deste trabalho.  \n\nA todos que contribu\u00edram pela realiza\u00e7\u00e3o deste trabalho.  \n\n \n\n \n\n\n\n1 \n \n\n \n\n1. Introdu\u00e7\u00e3o \n\nA express\u00e3o do fen\u00f3tipo masculino normal \u00e9 decorrente da a\u00e7\u00e3o dos andr\u00f3genos, \n\nhorm\u00f4nios esteroides importantes que apresentam fun\u00e7\u00f5es cruciais na diferencia\u00e7\u00e3o sexual \n\nmasculina. Os principais andr\u00f3genos circulantes em mam\u00edferos s\u00e3o a testosterona (T) e a \n\ndihidrotestosterona (DHT). Esses horm\u00f4nios esteroides s\u00e3o produzidos pelas gl\u00e2ndulas \n\nadrenais e pelas g\u00f4nadas, e desempenham um papel vital na reprodu\u00e7\u00e3o, especialmente na \n\ndiferencia\u00e7\u00e3o do sexo masculino durante o desenvolvimento fetal e na diferencia\u00e7\u00e3o sexual \n\nsecund\u00e1ria masculina e feminina (Hughes, 2001). \n\n \n\n1.1 O Receptor de Andr\u00f3genos \n\n \n\nO receptor de andr\u00f3genos [AR; Online Mendelian Inheritance in Man 313700], cuja \n\nfun\u00e7\u00e3o essencial \u00e9 o desenvolvimento do sexo masculino, \u00e9 um membro da superfam\u00edlia de \n\nfatores de transcri\u00e7\u00e3o nucleares ligantes-dependentes, que inclui os receptores para \n\nprogesterona, glicocorticoides, estr\u00f3genos, vitamina D, horm\u00f4nio tireoidiano e \u00e1cido \n\nretin\u00f3ico (Quigley et al., 1995). \n\nA ativa\u00e7\u00e3o dos andr\u00f3genos \u00e9 mediada pelos receptores acima mencionados, que por sua \n\nvez medeiam a diferencia\u00e7\u00e3o sexual masculina in utero e s\u00e3o respons\u00e1veis pelo \n\ndesenvolvimento e manuten\u00e7\u00e3o das caracter\u00edsticas sexuais masculinas (Ghali et al., 2003). \n\nA sequ\u00eancia de DNA complementar (cDNA) que codifica o receptor de andr\u00f3genos em \n\nhumanos foi elucidada em 1988 por diversos grupos quase que simultaneamente (Chang et \n\nal., 1988; Lubahn et al., 1988; Trapman et al., 1988; Tilley et al., 1989). Os autores \n\nmapearam o gene AR no cromossomo X, especificamente na regi\u00e3o Xq11-13, por\u00e9m, sua \n\nlocaliza\u00e7\u00e3o foi redefinida em 1993 por Brown e colaboradores localizando-o na regi\u00e3o \n\nXq11-12.  \n\nO gene AR em humanos \u00e9 composto por oito exons (Figura 1), separados por introns de \n\nat\u00e9 26 kb. A regi\u00e3o codificante do gene apresenta aproximadamente 2.757 pares de bases, \n\nque codificam uma prote\u00edna de aproximadamente 920 amino\u00e1cidos cujo peso molecular \u00e9 \n\nde aproximadamente 110 kDa (Lubahn et al., 1988). O n\u00famero de amino\u00e1cidos na prote\u00edna \n\n\n\n2 \n \n\nvaria e est\u00e1 diretamente relacionado ao n\u00famero de repeti\u00e7\u00f5es de glicinas e glutaminas \n\nencontrados em duas regi\u00f5es polim\u00f3rficas no dom\u00ednio N-terminal, como ser\u00e1 mostrado \n\nmais adiante. \n\n \n\n \n\n \n\n \n\nFigura 1: Esquema da localiza\u00e7\u00e3o e organiza\u00e7\u00e3o do gene e da prote\u00edna do receptor de \n\nandr\u00f3genos. Acima: cromossomo X, com destaque para a localiza\u00e7\u00e3o do gene AR na \n\nposi\u00e7\u00e3o Xq11-12. Ao centro: o gene AR com 75-90 kb de comprimento, dividido em 8 \n\nexons separados por 7 introns de at\u00e9 26 kb. Abaixo: o AR e os seus tr\u00eas dom\u00ednios, o \n\ndom\u00ednio N-terminal (NTD), o dom\u00ednio de liga\u00e7\u00e3o ao DNA (DBD), regi\u00e3o hinge (H) e o \n\ndom\u00ednio de liga\u00e7\u00e3o ao ligante (LBD) com sulco para a liga\u00e7\u00e3o da testosterona (T) e \n\ndiidrotestosterona (DHT). O exon 1 codifica o NTD (vermelho), os exons 2 e 3 codificam o \n\nDBD (verde). A regi\u00e3o 5' do exon 4 codifica a regi\u00e3o hinge (verde) e a parte restante do \n\nexon 4 juntamente com os exons 5-8 codificam o LBD (rosa) (Adaptado de Quigley et al., \n\n1995). \n\n \n\n \n\n \n\n \n\nGen\n\ne \n\ncD\n\nNA \n\n \n\n \nDHT/T \n\n \n\n \n\n \n\nProte\u00edna \n\ncDNA \n\nGene \n\n \nCromossomo X \n\n \n\n\n\n3 \n \n\n \n\n1.2 A Prote\u00edna do Receptor de Andr\u00f3genos \n\n \n\nO AR, assim como outros receptores nucleares, apresenta tr\u00eas diferentes dom\u00ednios \n\nfuncionais (Figura 1). O primeiro dom\u00ednio, chamado de dom\u00ednio de regula\u00e7\u00e3o \n\ntranscricional NH2 terminal domain (NTD), o segundo \u00e9 o dom\u00ednio de liga\u00e7\u00e3o ao DNA \n\n(DBD) e o terceiro corresponde ao dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio (LBD) (Ghali et al., \n\n2003; Tufan et al., 2005; Wu et al., 2010). H\u00e1 tamb\u00e9m uma regi\u00e3o de dobradi\u00e7a entre o \n\nDBD e LBD denominada regi\u00e3o hinge, que por conter o sinal de localiza\u00e7\u00e3o nuclear (NLS) \n\n\u00e9 respons\u00e1vel pela transloca\u00e7\u00e3o do complexo horm\u00f4nio-receptor do citoplasma para o \n\nn\u00facleo da c\u00e9lula (Quigley et al., 1995). \n\n \n\n1.2.1 Dom\u00ednio Regulador Transcricional \n\n \n\nO NTD que \u00e9 codificado pelo exon 1 do gene AR \u00e9 um extenso dom\u00ednio ativador da \n\ntranscri\u00e7\u00e3o. Sua extens\u00e3o corresponde a mais da metade da prote\u00edna AR e \u00e9 formado por \n\ncerca de 555 res\u00edduos aminoac\u00eddicos, n\u00famero este que pode variar. A varia\u00e7\u00e3o neste \n\nn\u00famero se deve \u00e0 presen\u00e7a de repeti\u00e7\u00f5es dos res\u00edduos de glutaminas (CAG) e glicinas \n\n(GGC) a partir dos res\u00edduos 57 e 450, respectivamente. Estas duas regi\u00f5es polim\u00f3rficas \n\nconferem uma variabilidade grande para a regi\u00e3o. Assim, o n\u00famero de repeti\u00e7\u00f5es CAG \n\npode variar, normalmente produzindo alelos com n\u00fameros de res\u00edduos entre 11 e 31. \n\nExistem varia\u00e7\u00f5es no n\u00famero destas repeti\u00e7\u00f5es entre diferentes grupos raciais. Na \n\npopula\u00e7\u00e3o negra, por exemplo, o alelo mais frequente apresenta 18 repeti\u00e7\u00f5es, ao passo que \n\nem popula\u00e7\u00f5es caucasianas o n\u00famero mais frequente \u00e9 21 (Quigley et al., 1995; Girardin et \n\nal., 2009). Estudos in vitro com alelos AR com mais de 40 repeti\u00e7\u00f5es CAG, mostraram uma \n\nredu\u00e7\u00e3o na atividade transcricional em compara\u00e7\u00e3o com mol\u00e9culas que apresentavam 20 a \n\n25 repeti\u00e7\u00f5es. Assim, pode-se deduzir que o n\u00famero de repeti\u00e7\u00f5es CAG esteja diretamente \n\nrelacionado \u00e0 atividade transcricional do gene AR (Hughes et al., 2006; Rajender et al., \n\n2007). A expans\u00e3o da regi\u00e3o de poliglutaminas para 40 a 65 res\u00edduos est\u00e1 associada \u00e0 \n\ns\u00edndrome de Kennedy, doen\u00e7a rara associada \u00e0 atrofia testicular, redu\u00e7\u00e3o na produ\u00e7\u00e3o de \n\nespermatoz\u00f3ides e infertilidade (Ferlin et al., 2006; Rajender et al., 2007). \n\n\n\n4 \n \n\nO n\u00famero de repeti\u00e7\u00f5es da trinca de nucleot\u00eddeos GGC, que corresponde ao amino\u00e1cido \n\nglicina, varia entre 16 a 27 res\u00edduos dentro da normalidade na popula\u00e7\u00e3o. Repeti\u00e7\u00f5es acima \n\ndesta faixa est\u00e3o associadas ao c\u00e2ncer de pr\u00f3stata e infertilidade masculina (Ferlin et al., \n\n2006). Por outro lado, o n\u00famero reduzido de repeti\u00e7\u00f5es GGC est\u00e1 associado \u00e0 redu\u00e7\u00e3o da \n\natividade transcricional do gene AR (Rajender et al., 2007). \n\nO polimorfismo do n\u00famero de glutaminas tem sido mais investigado do que o do \n\nn\u00famero de glicinas. Como as regi\u00f5es de DNA que codificam tanto a poliglutamina quanto a \n\npoliglicina s\u00e3o ricas em GC, a amplifica\u00e7\u00e3o por rea\u00e7\u00e3o em cadeia da polimerase (PCR) \n\ndestes fragmentos torna-se dif\u00edcil devido \u00e0 conforma\u00e7\u00e3o de fita simples que o DNA assume \n\nmediante a desnatura\u00e7\u00e3o e, tamb\u00e9m por este motivo, poucas muta\u00e7\u00f5es s\u00e3o descritas no exon \n\n1 (Yong et al., 2003; Rajender et al., 2007; Rong et al., 2010). \n\n O NTD \u00e9 o dom\u00ednio menos conservado entre os receptores nucleares (Claessens et al., \n\n2008). Neste dom\u00ednio, encontram-se regi\u00f5es essenciais para a a\u00e7\u00e3o transativadora do AR. A \n\nregi\u00e3o chamada activation function 1 (AF-1) \u00e9 importante, onde se encontram duas \n\nsubregi\u00f5es centrais com particular fun\u00e7\u00e3o na transativa\u00e7\u00e3o. Essas subregi\u00f5es s\u00e3o a Tau-1, \n\nlocalizada entre os res\u00edduos 101 e 370 e, a Tau-5, que se estende do res\u00edduo 360 ao 529, \n\nambas desempenham fun\u00e7\u00f5es atrav\u00e9s de intera\u00e7\u00f5es intramoleculares e intermoleculares \n\ncom co-reguladores. Al\u00e9m disso, os primeiros 30 amino\u00e1cidos do NTD s\u00e3o essenciais para \n\na intera\u00e7\u00e3o entre os terminais N e C do receptor, fundamental para a estabiliza\u00e7\u00e3o do \n\nligante e ativa\u00e7\u00e3o apropriada do AR, como observado na Figura 2 (McEwan et al., 2007; \n\nWerner et al., 2008). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n5 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 2: Representa\u00e7\u00e3o esquem\u00e1tica do AR_NTD (vermelho), DBD (verde) e LBD  \n\n(rosa). O motif FQNLF do NTD interage com o AF2 do LBD, levando a intera\u00e7\u00e3o N/C-\n\nterminal (acima). A regi\u00e3o Tau-1 do NTD cont\u00e9m a repeti\u00e7\u00e3o do amino\u00e1cido glutamina \n\n(Qn). J\u00e1 a regi\u00e3o Tau-5 apresenta a repeti\u00e7\u00e3o do amino\u00e1cido glicina (Gn). Ao ligar T/DHT, \n\no AF2 \u00e9 ativado e acontece a intera\u00e7\u00e3o com cofatores da transcri\u00e7\u00e3o. O esquema representa \n\na intera\u00e7\u00e3o entre o coativador p160 com NTD e LBD. LxxLL e Qr s\u00e3o motifs do coativador \n\np160, que se ligam diretamente com regi\u00f5es espec\u00edficas do AR. O sinal de localiza\u00e7\u00e3o \n\nnuclear (NLS) situado entre o DBD e LBD \u00e9 respons\u00e1vel pela transloca\u00e7\u00e3o do complexo \n\nhorm\u00f4nio/receptor do citoplasma para o n\u00facleo da c\u00e9lula (Esquema adaptado de Claessens \n\net al., 2008). \n\n \n\n1.2.2 Dom\u00ednio de liga\u00e7\u00e3o ao DNA \n\n \n\nO dom\u00ednio de liga\u00e7\u00e3o ao DNA (DBD), o mais conservado da prote\u00edna AR, situa-se  entre \n\nos amino\u00e1cidos 539 e 628, sendo seu tamanho de aproximadamente 80 amino\u00e1cidos. Este \n\ndom\u00ednio \u00e9 reconhecido pela presen\u00e7a de dois dedos de zinco (zinc finger). Os dedos de \n\nzinco apresentam estruturas e fun\u00e7\u00f5es diferentes e s\u00e3o codificados pelos exons 2 e 3, \n\nrespectivamente (Figura 3) (Melo et al., 2005; Rajender et al., 2007). \n\nIntera\u00e7\u00e3o N/C terminal \n\n\n\n6 \n \n\nS\u00e3o ligados ao zinco por quatro ciste\u00ednas, produzindo uma estrutura de h\u00e9lice-al\u00e7a-h\u00e9lice \n\nque interage com sequ\u00eancias especificas de DNA, os elementos de respostas hormonais \n\n(HRE) (Melo et al., 2005; Rajender et al., 2007). \n\nO reconhecimento da sequ\u00eancia alvo no DNA \u00e9 feita pelo primeiro dedo de zinco, que \n\napresenta uma sequ\u00eancia espec\u00edfica de cinco amino\u00e1cidos chamada de P-box, como \n\ndetalhado na figura 3. A regi\u00e3o P-box tamb\u00e9m \u00e9 encontrada em outros receptores capazes \n\nde reconhecer sequ\u00eancias espec\u00edficas no DNA, como exemplo, podemos citar os receptores \n\nde progesterona, glicocortic\u00f3ides e mineralocortic\u00f3ides (Clinckemalie et al., 2012). \n\nO segundo dedo de zinco \u00e9 respons\u00e1vel pela liga\u00e7\u00e3o do receptor ao DNA e por \n\nestabilizar a intera\u00e7\u00e3o DNA-prote\u00edna. Essa liga\u00e7\u00e3o acontece pelo contato com os \n\ngrupamentos fosfatos do DNA, tendo assim um papel fundamental em promover a ativa\u00e7\u00e3o \n\nda transcri\u00e7\u00e3o. Esse s\u00edtio est\u00e1 diretamente relacionado com a estabilidade da dimeriza\u00e7\u00e3o \n\ndo receptor (Giwercman et al., 2000; Hughes et al., 2006; Clinckemalie et al., 2012).   \n\n \n\n \n\n \n\nFigura 3: Estrutura do dom\u00ednio de liga\u00e7\u00e3o ao DNA e regi\u00e3o Hinge. O DBD apresenta dois \n\ndedos de zinco ligados. O primeiro dedo de zinco apresenta a regi\u00e3o P-box (proximal box) \n\nque est\u00e1 associada ao reconhecimento ao elemento de resposta hormonal (HRE) no DNA e \n\no segundo dedo de zinco, cont\u00e9m o D-box (distal box) que est\u00e1 envolvido na dimeriza\u00e7\u00e3o \n\ndo complexo horm\u00f4nio receptor. A regi\u00e3o hinge \u00e9 codificada pela por\u00e7\u00e3o 5\u2019 do exon 4 do \n\ngene AR e est\u00e1 associada a localiza\u00e7\u00e3o nuclear e a estabilidade do receptor (Clinckemalie et \n\nal., 2012). \n\n \n\n \n\n \n\n\n\n7 \n \n\n1.2.3 Regi\u00e3o hinge \n\n \n\nEntre os dom\u00ednios de liga\u00e7\u00e3o ao DNA e o dom\u00ednio de liga\u00e7\u00e3o ao andr\u00f3geno, encontra-se \n\na regi\u00e3o hinge. Esta regi\u00e3o \u00e9 codificada pela por\u00e7\u00e3o 5\u2019 do exon 4 do gene AR (Figura 3). Os \n\namino\u00e1cidos localizados entre as posi\u00e7\u00f5es 629 at\u00e9 669 comp\u00f5em esta regi\u00e3o, tamb\u00e9m  \n\nconhecida como regi\u00e3o de dobradi\u00e7a. Nesta regi\u00e3o, especificamente os amino\u00e1cidos \n\n629\nRKLKKL\n\n634\n, encontra-se a regi\u00e3o necess\u00e1ria para a transloca\u00e7\u00e3o do complexo \n\nandr\u00f3geno/receptor do citoplasma para o n\u00facleo da c\u00e9lula (NLS). Al\u00e9m desta fun\u00e7\u00e3o, pode-\n\nse atribuir \u00e0 regi\u00e3o hinge outras fun\u00e7\u00f5es como regular o potencial transcricional e a \n\nestabilidade do receptor, promover a mobiliza\u00e7\u00e3o intra-nuclear, al\u00e9m de ser alvo de \n\nmodifica\u00e7\u00f5es p\u00f3s-traducionais (Helsen et al., 2012, Rajender et al., 2007, Wong, et al., \n\n2008, Clinckemalie et al., 2012). Clinckemalie e colaboradores (2012) descrevem em seu \n\ntrabalho a import\u00e2ncia desta regi\u00e3o tamb\u00e9m na intera\u00e7\u00e3o com co-reguladores. Muta\u00e7\u00f5es ou \n\ndele\u00e7\u00f5es nesta regi\u00e3o podem resultar em um preju\u00edzo dr\u00e1stico na capacidade de liga\u00e7\u00e3o \n\ncom o DNA, por\u00e9m, curiosamente aumentam o potencial de transativa\u00e7\u00e3o desse gene. \n\nProcessos sub-nucleares evidenciam a import\u00e2ncia dessa regi\u00e3o no recrutamento de \n\ncofatores, por\u00e9m este mecanismo ainda n\u00e3o foi esclarecido (Helsen et al., 2012, Rajender et \n\nal., 2007, Wong, et al. 2008, Wu et al., 2010, Quigley et al., 1995, Tanner et al., 2010). \n\n \n\n1.2.4 Dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio  \n\n \n\nO dom\u00ednio LBD \u00e9 o segundo dom\u00ednio mais conservado, tamb\u00e9m conhecido como \n\ncarboxi-terminal domain (CTD), localiza-se entre os amino\u00e1cidos 670 a 920 (Figura 1). \n\nNeste dom\u00ednio, encontra-se o subdom\u00ednio activation function 2 (AF-2). Este subdom\u00ednio \n\napresenta uma regi\u00e3o altamente conservada na regi\u00e3o carboxi-terminal deste receptor, \n\nfundamental para a transativa\u00e7\u00e3o deste gene (Figura 2). Depois da liga\u00e7\u00e3o com o \n\nandr\u00f3geno, as prote\u00ednas de choque t\u00e9rmico que mant\u00e9m o AR desativado s\u00e3o liberadas. O \n\ncomplexo horm\u00f4nio/receptor dimeriza-se e \u00e9 transportado para o n\u00facleo celular onde \u00e9 \n\nativado por mudan\u00e7as conformacionais na h\u00e9lice 12 desta prote\u00edna, que favorece a \n\nintera\u00e7\u00e3o entre os dom\u00ednios N/C terminais (NTD e CTD) atrav\u00e9s das h\u00e9lices 3, 4 e 12 \n\n(Jaaskelain et al. 2006). O AF-2 forma uma fenda hidrof\u00f3bica que se liga ao LXXLL motif \n\n\n\n8 \n \n\n(L representa o amino\u00e1cido leucina e o X representa outro amino\u00e1cido), dos co-ativadores \n\n(SRC)/p160. O subdom\u00ednio AF-2 tamb\u00e9m se liga com alta afinidade ao FQNLF motif, \n\nlocalizado no dom\u00ednio NH2 do AR (Figura 2). Estas liga\u00e7\u00f5es intramoleculares s\u00e3o \n\nconhecidas como intera\u00e7\u00f5es N/C terminais, como representado na figura 2 (Werner et al., \n\n2008). Atualmente, este tipo de intera\u00e7\u00e3o tem sido usada para relacionar a capacidade de \n\ntransativa\u00e7\u00e3o do AR e o preju\u00edzo associado ao fen\u00f3tipo do paciente. Ensaios sobre \n\nintera\u00e7\u00f5es N/C terminais t\u00eam-se comprovado \u00fateis como ferramentas importantes em casos \n\nde s\u00edndrome da Insensibilidade Androg\u00eanica (AIS, do ingl\u00eas Androgen Insensibility \n\nSyndrome) onde muta\u00e7\u00f5es no LBD n\u00e3o provocam preju\u00edzos na liga\u00e7\u00e3o ao horm\u00f4nio \n\n(Jaaskelain et al., 2006; Werner et al., 2008).  \n\nAinda no dom\u00ednio LBD, encontra-se e a regi\u00e3o denominada androgen receptor binding \n\nfunction-3 (AR BF-3) que compreende os amino\u00e1cidos Ile-672, Phe-673, Pro-723, Gly-724, \n\nAsn-727, Phe-826, Glu-829, Asn-833, Glu-837 e Arg-840. Assim como o subdom\u00ednio AF-\n\n2, a regi\u00e3o BF-3 \u00e9 altamente conservada entre os receptores de ester\u00f3ides (Perpina et al., \n\n2007). Estudos revelam que a regi\u00e3o BF-3 \u00e9 um hot spot para muta\u00e7\u00f5es que est\u00e3o \n\nassociadas ao c\u00e2ncer de pr\u00f3stata e \u00e0 AIS (Buzon et al.,2011, Perpina et al., 2007). Buz\u00f3n e \n\ncolaboradores (2011), sugerem em suas an\u00e1lises estruturais que existe uma rela\u00e7\u00e3o direta \n\nentre AF-2 e BF-3 no recrutamento de co-ativadores. Ainda nesse trabalho, os autores \n\nreferem-se \u00e0 regi\u00e3o BF-3 como uma potencial candidata para o desenvolvimento de \n\nf\u00e1rmacos (Buzon et al.,2011, Perpina et al., 2007).  \n\n \n\n1.3 A\u00e7\u00e3o Androg\u00eanica \n\n \n\nOutras prote\u00ednas importantes na a\u00e7\u00e3o androg\u00eanica s\u00e3o as chaperonas, como a HSP70, \n\nHSP90, HSP40 e FKBP52, essenciais para o estabelecimento da liga\u00e7\u00e3o do complexo \n\nhorm\u00f4nio/receptor, transloca\u00e7\u00e3o do complexo do citoplasma para seu s\u00edtio de a\u00e7\u00e3o nuclear, \n\nacelerar a transcri\u00e7\u00e3o mediada pelo AR e manuten\u00e7\u00e3o da prote\u00edna AR (Figura 4) (Nitsche e \n\nHiort, 2000; Heemers e Tindall, 2007). \n\nA transativa\u00e7\u00e3o do AR \u00e9 dada pela intera\u00e7\u00e3o entre diferentes subdom\u00ednios da prote\u00edna \n\nAR. Como j\u00e1 citado, os subdom\u00ednios mais conhecidos que atuam diretamente neste \n\nprocesso s\u00e3o os subdom\u00ednios AF1, localizado no dom\u00ednio amino-terminal e o subdom\u00ednio \n\n\n\n9 \n \n\nAF2, localizado no dom\u00ednio carboxi-terminal da prote\u00edna AR. Intera\u00e7\u00f5es entre AF1 e AF2 \n\ns\u00e3o comprovadamente necess\u00e1rias para a transativa\u00e7\u00e3o desse receptor (Werner et al., 2008). \n\nDele\u00e7\u00f5es no dom\u00ednio LBD podem abolir completamente a liga\u00e7\u00e3o com o horm\u00f4nio e \n\nconsequentemente a fun\u00e7\u00e3o do AR. Dele\u00e7\u00f5es na regi\u00e3o N-terminal que \u00e9 o dom\u00ednio NTD, \n\nn\u00e3o afetam a capacidade de liga\u00e7\u00e3o com o ligante, por\u00e9m, podem afetar a capacidade de \n\ntransativa\u00e7\u00e3o do AR devido \u00e0 presen\u00e7a dos subdom\u00ednio AF1 nesta regi\u00e3o. \n\nEntre as co-chaperonas que promovem a a\u00e7\u00e3o androg\u00eanica, podemos citar a FKBP52, \n\nque tem sido estudada em rela\u00e7\u00e3o \u00e0 sua atua\u00e7\u00e3o nos mecanismos de atividade androg\u00eanica e \n\ntamb\u00e9m quanto seu papel no fen\u00f3tipo de indiv\u00edduos com hipospadias (Cheung-Flynn et al., \n\n2005; Cox et al., 2007; Beleza-Meireles et al., 2007; Chen et al., 2010). Embora tenha \n\ncomprovadamente um papel importante na a\u00e7\u00e3o transcricional do receptor de andr\u00f3genos, \n\nnenhuma muta\u00e7\u00e3o no gene FKBP4, que a codifica, foi identificada. Provavelmente, isto se \n\ndeva ao fato de as triagens de muta\u00e7\u00f5es em indiv\u00edduos com os v\u00e1rios graus de \n\ninsensibilidades androg\u00eanicas serem ainda incipientes.  \n\nEm um estudo feito por Sunnotel e colaboradores (2010) ficou demonstrado que o fator \n\nFKBPL \u00e9 expresso em altas quantidades em test\u00edculo de rato, sendo que essa express\u00e3o \n\naumenta na puberdade. A prote\u00edna FKBPL humana \u00e9 expressa nos test\u00edculos em um padr\u00e3o \n\nsemelhante ao da FKBP52 e tamb\u00e9m \u00e9 capaz de aumentar a atividade transcricional do \n\ngene AR em ensaios com gene-reporter (Sunnotel et al., 2010).  Em tal trabalho, que \n\ndescreve muta\u00e7\u00f5es no gene FKBPL, ficou clara a import\u00e2ncia dos genes que codificam co-\n\nchaperonas na regula\u00e7\u00e3o da atividade androg\u00eanica. \n\n \n\n \n\n \n\n               \n\n\n\n10 \n \n\n \n\n \n\nFigura 4: Esquema do mecanismo molecular do receptor de andr\u00f3genos. O receptor de \n\nandr\u00f3genos \u00e9 ativado ap\u00f3s a entrada de testosterona e/ou dihidrotestosterona no citoplasma \n\nda c\u00e9lula. A ativa\u00e7\u00e3o do receptor envolve a dissocia\u00e7\u00e3o de prote\u00ednas inibit\u00f3rias associadas \n\nao receptor, como as heat-shock proteins (HSPs). Depois da liga\u00e7\u00e3o com o horm\u00f4nio, \n\nacontece a fosforila\u00e7\u00e3o e dimeriza\u00e7\u00e3o do receptor. No n\u00facleo, os d\u00edmeros ligam-se aos \n\nelementos de resposta ao horm\u00f4nio (ARE), recrutam cofatores para a inicia\u00e7\u00e3o da \n\ntranscri\u00e7\u00e3o de genes alvo e assim acontecem os efeitos biol\u00f3gicos (Adaptado de Meehan e \n\nSadar, 2003).  \n\n \n\n1.4 Muta\u00e7\u00f5es no Gene AR \n\n \n\nA atua\u00e7\u00e3o dos horm\u00f4nios testosterona e diidrotestosterona s\u00f3 acontecem quando o \n\nreceptor para esses andr\u00f3genos e todos os mecanismos relacionados \u00e0 a\u00e7\u00e3o androg\u00eanica \n\nest\u00e3o e \u00edntegros. Assim, a a\u00e7\u00e3o desses horm\u00f4nios ocorrer\u00e1, permitindo sua atua\u00e7\u00e3o no \n\ndesenvolvimento fetal e na diferencia\u00e7\u00e3o da genit\u00e1lia masculina normal (Heemers e \n\nTindall, 2007). \n\nQuando o gene AR apresenta alguma altera\u00e7\u00e3o ou outros genes de alguma prote\u00edna \n\nenvolvida na a\u00e7\u00e3o androg\u00eanica n\u00e3o se encontram em suas formas \u00edntegras, ocorrer\u00e1 um \n\npreju\u00edzo na a\u00e7\u00e3o do horm\u00f4nio e o indiv\u00edduo apresentar\u00e1 a AIS (OMIM 300068) (Heemers e \n\nTindall, 2007). \n\nA AIS est\u00e1 associada principalmente a muta\u00e7\u00f5es no gene AR, por\u00e9m pode ser associada \n\na outros eventos envolvendo a atua\u00e7\u00e3o dos andr\u00f3genos, desde a liga\u00e7\u00e3o do andr\u00f3geno ao \n\nreceptor, at\u00e9 sua a\u00e7\u00e3o nuclear (Werner et al., 2006). Dependendo da gravidade da altera\u00e7\u00e3o, \n\nTESTOSTERONA \n\nCITOPLASMA \n\nN\u00daCLEO \n\nTRADU\u00c7\u00c3O \n\n  EFEITOS BIOL\u00d3GICOS \n\n\n\n11 \n \n\npodemos associ\u00e1-la aos fen\u00f3tipos completo, parcial ou brando da insensibilidade \n\nandrog\u00eanica.  \n\nMais de 800 muta\u00e7\u00f5es constam do banco de muta\u00e7\u00f5es espec\u00edfico do gene AR \n\n(http://androgendb.mcgill.ca/AR23.pdf, Gottlieb et al., 2012), sendo que 15% foram \n\nencontradas no dom\u00ednio ativador da transcri\u00e7\u00e3o, 20% no dom\u00ednio de liga\u00e7\u00e3o ao DNA e \n\n55% no dom\u00ednio de liga\u00e7\u00e3o aos andr\u00f3genos.  \n\nA maioria das muta\u00e7\u00f5es encontradas no gene AR \u00e9 do tipo missense. Este tipo de \n\nmuta\u00e7\u00e3o, conhecido pela substitui\u00e7\u00e3o de amino\u00e1cidos isolados pode estar associado a todos \n\nos fen\u00f3tipos atribu\u00eddos a insensibilidade androg\u00eanica. A localiza\u00e7\u00e3o das muta\u00e7\u00f5es est\u00e1 \n\nrelacionada diretamente \u00e0 manifesta\u00e7\u00e3o da doen\u00e7a. Muta\u00e7\u00f5es localizadas no subdom\u00ednio \n\nAF-2 da prote\u00edna AR, geralmente est\u00e3o associadas \u00e0 forma CAIS (do ingl\u00eas complete \n\nandrogen insensitivity syndrome) ou parcial grave (Galani et al., 2008; Wu et al., 2010; \n\nPetroli et al., 2011). \n\nN\u00e3o muito frequente, mas tamb\u00e9m relacionada a AIS, s\u00e3o as muta\u00e7\u00f5es que conduzem \u00e0 \n\naltera\u00e7\u00e3o no quadro de leitura (muta\u00e7\u00f5es frameshift), inser\u00e7\u00f5es ou dele\u00e7\u00f5es de nucleot\u00eddeos, \n\naltera\u00e7\u00f5es no mecanismo de splicing ou at\u00e9 dele\u00e7\u00f5es de grandes segmentos deste gene. \n\nTodas essas muta\u00e7\u00f5es podem interromper ou alterar a sequ\u00eancia prim\u00e1ria da prote\u00edna e \n\nest\u00e3o associadas ao fen\u00f3tipo CAIS (Maciel-Guerra et al., 2002; Galani et al., 2008; \n\nBrinkmann et al., 2011). \n\n \n\n1.5 A Insensibilidade Androg\u00eanica \n\n \n\nA insensibilidade androg\u00eanica \u00e9 a causa mais comum de dist\u00farbios da diferencia\u00e7\u00e3o do \n\nsexo em indiv\u00edduos com cari\u00f3tipo 46, XY. O espectro fenot\u00edpico dessa s\u00edndrome pode \n\nvariar desde indiv\u00edduos com fen\u00f3tipo tipicamente feminino, com test\u00edculos, com mamas e  \n\ndesenvolvimento reduzido de p\u00ealos at\u00e9 indiv\u00edduos com fen\u00f3tipo masculino, geralmente \n\ncom ginecomastia, podendo ou n\u00e3o apresentar comprometimento na fertilidade (Figura 5) \n\n(Larrea et al.,1978; Quigley et al., 1995; Yong et al., 1998; Giwercman et al., 2000; \n\nBoehmer et al., 2001). \n\nOs primeiros casos de AIS foram relatados por Morris em 1953, data que ficou \n\nconhecida como um marco hist\u00f3rico no estudo desta doen\u00e7a (Morris, 1953). Em seu \n\nhttp://androgendb.mcgill.ca/AR23.pdf\n\n\n12 \n \n\ntrabalho, Morris avaliou 82 casos, inicialmente conhecidos como \"test\u00edculos feminilizantes\" \n\n(Quigley et al., 1995, Hughes et al., 2006). Como sinais cl\u00ednicos de AIS, foram \n\nestabelecidos os crit\u00e9rios: genit\u00e1lia externa feminina, com aus\u00eancia de genitais internos \n\nfemininos, exceto \u00fatero rudimentar, trompas uterinas ou ductos esperm\u00e1ticos, em alguns \n\npacientes; desenvolvimento mam\u00e1rio feminino normal; aus\u00eancia ou escassez de p\u00ealos \n\npubianos e axilares; g\u00f4nadas com t\u00fabulos semin\u00edferos, aus\u00eancia de espermatog\u00eanese e \n\naumento das c\u00e9lulas intersticiais; h\u00e1bito feminino (Quigley et al., 1995). \n\nDados de frequ\u00eancia na popula\u00e7\u00e3o ainda s\u00e3o imprecisos. Na popula\u00e7\u00e3o dinamarquesa, a \n\nincid\u00eancia \u00e9 estimada entre 1:20.400 a 1:99.000 rec\u00e9m-nascidos com sexo gen\u00e9tico \n\nmasculino (Quigley et al., 1995; Hughes et al., 2006).  \n\nPor ser uma anomalia recessiva ligada ao cromossomo X, somente indiv\u00edduos com sexo \n\ngen\u00e9tico 46,XY s\u00e3o afetados por AIS, enquanto que indiv\u00edduos com sexo feminino 46,XX \n\npodem ser portadores e transmiti-la para a sua prole, por\u00e9m sem manifestar o quadro \n\ncl\u00ednico da doen\u00e7a (Hiort et al., 2000). Em 70% dos casos, os indiv\u00edduos com caracter\u00edsticas \n\ncl\u00ednicas de AIS herdam a muta\u00e7\u00e3o da m\u00e3e, enquanto os 30% restantes s\u00e3o de muta\u00e7\u00f5es de \n\nnovo (Kohler et al., 2005).  \n\nPara a classifica\u00e7\u00e3o da genit\u00e1lia de indiv\u00edduos com AIS, Quigley e colaboradores (1995) \n\nprop\u00f5em 7 graus diferentes, ordenados de acordo com a gravidade da resist\u00eancia \n\nandrog\u00eanica (Figura 5). De acordo com esta classifica\u00e7\u00e3o, as genit\u00e1lias s\u00e3o diferenciadas de \n\nacordo com o grau de viriliza\u00e7\u00e3o, iniciando-se no grau 1, que inclui indiv\u00edduos com \n\nresposta normal aos andr\u00f3genos durante o desenvolvimento fetal e genit\u00e1lia externa normal, \n\nsendo caracterizado por homens com ginecomastia e inf\u00e9rteis ou, mais raro, f\u00e9rteis. Esses \n\npacientes se enquadram no fen\u00f3tipo leve desta s\u00edndrome, conhecida como MAIS (do ingl\u00eas \n\nmild androgen insensitivity syndrome). A forma parcial, conhecida por PAIS (do ingl\u00eas \n\npartial androgen insensitivity syndrome) \u00e9 classificada entre os graus 2 ao 6, podendo \n\nvariar desde ambiguidade genital at\u00e9 genit\u00e1lia t\u00edpica feminina com pilifica\u00e7\u00e3o. J\u00e1 \n\nindiv\u00edduos com a resist\u00eancia completa aos andr\u00f3genos, forma CAIS \u00e9 classificada como \n\ngrau 7 e compreende indiv\u00edduos com fen\u00f3tipo feminino, por\u00e9m sem desenvolvimento de \n\np\u00ealos pubianos e axilares na puberdade. \n\n \n\n\n\n13 \n \n\n \n\nFigura 5: Classifica\u00e7\u00e3o dos graus de viriliza\u00e7\u00e3o da genit\u00e1lia externa em indiv\u00edduos com \n\nAIS, de acordo com a gravidade da resist\u00eancia androg\u00eanica (Quigley et al., 1995). Em 1, \n\ngenit\u00e1lia masculina t\u00edpica, observado em casos de insensibilidade branda aos andr\u00f3genos. \n\nEm 2, compreende indiv\u00edduos com fen\u00f3tipo masculino com manifesta\u00e7\u00e3o de hiposp\u00e1dia. \n\nEm 3, engloba indiv\u00edduos com fen\u00f3tipo predominantemente masculino, com anomalias \n\ngraves na masculiniza\u00e7\u00e3o, hipospadias perineal, p\u00eanis diminuido com criptorquidia. Em 4, \n\ncompreende indiv\u00edduos com limita\u00e7\u00f5es na masculiniza\u00e7\u00e3o, com falo intermedi\u00e1rio entre \n\nclit\u00f3ris e p\u00eanis. Em 5, indiv\u00edduos com fen\u00f3tipo feminino, com m\u00ednima a\u00e7\u00e3o androg\u00eanica no \n\nper\u00edodo fetal, separa\u00e7\u00e3o entre uretra e orif\u00edcio vaginal, leve clitoromegalia e/ou pequeno \n\ngrau de fus\u00e3o labial posterior. Em 6, compreende indiv\u00edduos com genit\u00e1lia feminina \n\nnormal, sem atua\u00e7\u00e3o de andr\u00f3genos no desenvolvimento fetal, com p\u00ealos pubianos e \n\naxilares. De 2-6 compreende indiv\u00edduos com a forma parcial da insensibilidade \n\nandrog\u00eanica. Em 7, compreende indiv\u00edduos com genit\u00e1lia feminina normal, sem atua\u00e7\u00e3o de \n\nandr\u00f3genos no desenvolvimento fetal, sem desenvolvimento de p\u00ealos pubianos e axilares  \n\nna puberdade, caracterizando a forma completa da AIS (Quigley et al.,1995). \n\n1.5.1 A Insensibilidade Completa aos Andr\u00f3genos \n\n \n\nA forma mais grave da resist\u00eancia aos andr\u00f3genos, conhecida por insensibilidade \n\ncompleta a andr\u00f3genos, \u00e9 caracterizada pela perda completa da fun\u00e7\u00e3o do receptor de \n\nandr\u00f3geno. \n\nA CAIS acomete indiv\u00edduos 46,XY que produzem normalmente testosterona na \n\nvida fetal e na puberdade. Por\u00e9m, tanto a genit\u00e1lia quanto os outros org\u00e3os-alvo n\u00e3o \n\nrespondem aos andr\u00f3genos nessas fases, causando diferencia\u00e7\u00e3o feminina da genit\u00e1lia \n\nexterna e do seio urogenital, al\u00e9m de feminiliza\u00e7\u00e3o na puberdade. \n\n\n\n14 \n \n\nO diagn\u00f3stico dessa s\u00edndrome pode ser realizado logo ap\u00f3s o nascimento, devido \u00e0 \n\npresen\u00e7a de test\u00edculos palp\u00e1veis e \u00e0 discrep\u00e2ncia entre o cari\u00f3tipo 46,XY e o fen\u00f3tipo dos \n\npacientes, tipicamente feminino. No entanto, muitos casos podem n\u00e3o ter diagn\u00f3stico \n\nprecoce e na inf\u00e2ncia. Nesses casos, o diagn\u00f3stico acontece na puberdade, pela amenorr\u00e9ia \n\nprim\u00e1ria e aus\u00eancia de p\u00ealos (Quigley et al., 1995). A manifesta\u00e7\u00e3o cl\u00ednica mais comum \u00e9 a \n\npresen\u00e7a de h\u00e9rnia inguinal bilateral. Segundo Galani e colaboradores (2008), a preval\u00eancia \n\nde pacientes com AIS e h\u00e9rnia inguinal acontece em 1 a 2% desses casos.  \n\n  O fen\u00f3tipo cl\u00e1ssico atribu\u00eddo \u00e0 forma CAIS caracteriza-se como aus\u00eancia de ductos \n\ngenitais internos, vagina em fundo cego e genit\u00e1lia externa feminina normal, exceto pela \n\npresen\u00e7a frequente de g\u00f4nadas inguinais ou labioescrotais. Indiv\u00edduos com CAIS \n\napresentam desenvolvimento feminino t\u00edpico na puberdade, com distribui\u00e7\u00e3o de gordura \n\nginec\u00f3ide e p\u00ealos sexuais escassos ou ausentes, mamas t\u00eam caracter\u00edsticas femininas \n\nnormais, contornos corporais femininos e aus\u00eancia de acne, devido \u00e0 produ\u00e7\u00e3o de estr\u00f3geno \n\npelos test\u00edculos e pela aromatiza\u00e7\u00e3o perif\u00e9rica da testosterona em estradiol (Guigley et al., \n\n1995; Rajender et al., 2007).  \n\n \n\n1.5.2 Insensibilidade Parcial aos Andr\u00f3genos \n\n \n\n Ao contr\u00e1rio do fen\u00f3tipo relativamente uniforme dos casos da CAIS, a PAIS \n\n(OMIM 312300) \u00e9 caracterizada por indiv\u00edduos com diferentes fen\u00f3tipos devido ao defeito \n\nparcial na fun\u00e7\u00e3o do receptor de andr\u00f3geno, que pode variar. Os pacientes com PAIS \n\napresentam diferentes graus de masculiniza\u00e7\u00e3o da genit\u00e1lia externa, interna e do seio \n\nurogenital. Devido ao grande n\u00famero de fen\u00f3tipos que podem estar associados a PAIS, a \n\npreval\u00eancia desta s\u00edndrome ainda \u00e9 desconhecida (Ragender et al., 2007). \n\n \n\n1.5.3 Insensibilidade Leve aos Andr\u00f3genos \n\n \n\nIndiv\u00edduos que apresentam ginecomastia com fertilidade comprometida ou n\u00e3o s\u00e3o \n\nclassificados na forma MAIS, como descritos anteriormente. A fertilidade em pacientes \n\ncom AIS \u00e9 extremamente rara, com poucos casos descritos na literatura (Larrea et al.,1978, \n\nYong et al., 1994, Giwercman et al., 2000). Segundo Ferlin e colaboradores (2006), 2 a 3% \n\n\n\n15 \n \n\nde infertilidade masculina s\u00e3o causados por muta\u00e7\u00f5es no gene AR, em pacientes com \n\nfen\u00f3tipo MAIS.  \n\nEmbora muta\u00e7\u00f5es no gene AR estejam diretamente associadas \u00e0 insensibilidade \n\nandrog\u00eanica, em alguns casos essa s\u00edndrome se manifesta mesmo com o gene AR em sua \n\nforma \u00edntegra. Como a a\u00e7\u00e3o androg\u00eanica \u00e9 um evento complexo, n\u00e3o pode ser descartada a \n\nhip\u00f3tese de co-reguladores da transcri\u00e7\u00e3o n\u00e3o estarem atuando em sua forma normal, o que \n\npoderia explicar a manifesta\u00e7\u00e3o desta s\u00edndrome nestes casos. \n\nAdachi e colaboradores (2000) descreveram o caso de uma mulher de 19 anos de idade, \n\ncom amenorr\u00e9ia prim\u00e1ria e resist\u00eancia completa a andr\u00f3genos. Este diagn\u00f3stico foi baseado \n\nnos dados cl\u00ednicos, citogen\u00e9ticos e hormonais. No estudo do gene AR desta paciente, no \n\nentanto, nenhuma altera\u00e7\u00e3o que comprovasse o fen\u00f3tipo foi observada. Segundo os autores, \n\num poss\u00edvel preju\u00edzo na intera\u00e7\u00e3o do receptor de andr\u00f3genos com co-reguladores estaria \n\nimpedindo a a\u00e7\u00e3o androg\u00eanica nesta paciente. \n\nNeste trabalho, descrevemos a atividade funcional de sete muta\u00e7\u00f5es, sendo uma \n\nrelacionada ao fen\u00f3tipo MAIS, tr\u00eas ao fen\u00f3tipo PAIS e tr\u00eas ao fen\u00f3tipo CAIS. A forma \n\nmais grave da PAIS est\u00e1 descrita no artigo 1, no artigo 2 ser\u00e3o apresentados os estudos \n\nfuncionais de muta\u00e7\u00f5es associadas \u00e0s formas PAIS e CAIS e no artigo 3, descrevemos o \n\nestudo da muta\u00e7\u00e3o p.Pro695Ser encontrada em um paciente com fen\u00f3tipo masculino cuja \n\n\u00fanica queixa era ginecomestia, com fertilidade preservada. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n16 \n \n\n2. Objetivos \n\n \n\n2.1 Objetivos gerais: \n\n \n\n \n\n \n\n? Investigar quais os preju\u00edzos na atividade de transativa\u00e7\u00e3o do AR, causados por novas \n\nmuta\u00e7\u00f5es. \n\n \n\n? Analisar como acontece a intera\u00e7\u00e3o entre os dom\u00ednios amino-terminal e carboxi-terminal \n\ndo receptor de andr\u00f3geno mutante.  \n\n \n\n? Associar os preju\u00edzos funcionais dos AR mutantes com os fen\u00f3tipos associados \u00e0s diversas \n\nformas de AIS. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n17 \n \n\n2.2 Objetivos Espec\u00edficos: \n\n \n\n2.2.1 Artigo 1: \n\n? Analisar o gene AR em uma fam\u00edlia com quadro sugestivo de insensibilidade androg\u00eanica, \n\natrav\u00e9s do sequenciamento autom\u00e1tico. \n\n? Realizar o estudo estrutural in silico das trocas aminoac\u00eddicas com base na estrutura da \n\nprote\u00edna AR previamente publicada (PDB-ID: 2AM9); \n\n? Relacionar o gen\u00f3tipo com o fen\u00f3tipo dos pacientes. \n\n \n\n2.2.2 Artigo 2: \n\n \n\n? Investigar as propriedades funcionais de sete muta\u00e7\u00f5es individuais e uma combina\u00e7\u00e3o de \n\nduas muta\u00e7\u00f5es, avaliando o impacto na atividade de transativa\u00e7\u00e3o e na intera\u00e7\u00e3o entre os \n\ndom\u00ednios N-terminal e C-terminal do receptor de andr\u00f3genos. \n\n \n\n? Relacionar os graus de comprometimento da fun\u00e7\u00e3o do receptor com os fen\u00f3tipos dos \n\npacientes.  \n\n \n\n2.2.3 Artigo 3: \n\n? Investigar a atividade transcricional da prote\u00edna AR em um paciente com ginecomastia e \n\nfertilidade preservada. \n\n? Analisar se a muta\u00e7\u00e3o p.Pro695Ser \u00e9 respons\u00e1vel por alguma altera\u00e7\u00e3o entre as intera\u00e7\u00f5es \n\nN/C terminal neste paciente.  \n\n \n\n \n\n \n\n \n\n \n\n\n\n18 \n \n\n3. Cap\u00edtulo 1 \n\n \n\nArtigo 1: \n\n \n\nSevere forms of partial androgen insensitivity \n\nsyndrome due to p.L830F novel mutation in \n\nandrogen receptor gene in a Brazilian family \n \n\nReginaldo  J Petroli, Andr\u00e9a   T Maciel-Guerra, Fernanda  C Soardi, Fl\u00e1via  L de Calais, Gil Guerra-\n\nJunior\n  \nand Maricilda Palandi de Mello.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n19 \n \n\n \n\n \n\n \n\n\n\n20 \n \n\n \n\n \n\n \n\n\n\n21 \n \n\n \n\n\n\n22 \n \n\n \n\n \n\n\n\n23 \n \n\n \n\n \n\n\n\n24 \n \n\n \n\n \n\n \n\n\n\n25 \n \n\n \n\n \n\n4. Cap\u00edtulo 2 \n\n \n\nArtigo 2: \n\n \n\nFunctional analysis of six androgen receptor \n\nmutations identified in patients with complete \n\nand partial androgen insensitivity syndrome \n\nReginaldo J Petroli, Olaf Hiort, Dagmar Struve, Fernanda Caroline Soardi, Karla Melo, Ivo \n\nJorge Prado Arnhold, Andr\u00e9a Trevas Maciel-Guerra, Gil Guerra-Junior, Ralf Werner and \n\nMaricilda Palandi de Mello. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n26 \n \n\nFunctional analysis of six androgen receptor mutations identified in patients with \n\ncomplete and partial androgen insensitivity syndrome \n\nReginaldo J Petroli\na,b\n\n, Olaf Hiort\nb\n, Dagmar Struve\n\nb\n, Fernanda Caroline Soardi\n\na\n, Karla \n\nMelo\nc\n, Ivo Jorge Prado Arnhold\n\nc\n, Andr\u00e9a Trevas Maciel-Guerra\n\nd\n, Gil Guerra-Junior\n\ne\n, Ralf \n\nWerner\nb\n and Maricilda Palandi de Mello\n\na\n \n\n \na\n Centro de Biologia Molecular e Engenharia Gen\u00e9tica, Universidade Estadual de \n\nCampinas, Campinas, S\u00e3o Paulo, Brasil; \nb\n Department of Paediatrics and Adolescent \n\nMedicine, Division of Experimental Paediatric Endocrinology and Diabetes, University of \n\nLuebeck, Luebeck, Germany; \nc\n Unidade de Endocrinologia do Desenvolvimento, \n\nLaborat\u00f3rio de Horm\u00f4nios de Gen\u00e9tica Molecular LIM/42, Divis\u00e3o de Endocrinologia, \n\nHospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, \n\nBrasil; \nd \n\nDepartamento de Gen\u00e9tica M\u00e9dica, Universidade Estadual de Campinas, \n\nCampinas, S\u00e3o Paulo, Brasil; \ne \nDepartamento de Pediatria, Universidade Estadual de \n\nCampinas, Campinas, S\u00e3o Paulo, Brasil. \n\n \n\nRunning title: Functional studies on androgen receptor mutations \n\nCorresponding author: \n\nMaricilda Palandi de Mello \n\nCBMEG-Unicamp \n\nAv. C\u00e2ndido Rondon 400 \n\n13083-875 Campinas, SP \n\nBrasil   \n\n\n\n27 \n \n\n \n\nAbstract \n\nThe androgens are responsible for development and maintenance of male sex secondary \n\ncharacteristics. Dysfunctions in androgen action due mutations in androgen receptor (AR) \n\ngene can lead to androgen insensitivity syndrome (AIS). Depending on the impairment \n\nowing AR gene mutations, AIS manifestation can be mild, partial or complete. Here, we \n\nhave analyzed the effects of p.Ser759Thr, p.Leu830Phe and p.Ile898Phe, p.Leu768Val, \n\np.Cys806Phe+p.Gln798Glu, and p.Pro904Arg missense mutations that were clinically \n\nassociated to partial AIS (PAIS) or to complete AIS (CAIS). All mutations have been \n\nidentified by AR gene sequencing. To evaluate the transactivation ability of each AR \n\nmutant, the site-directed mutagenesis assay was performed on full-length AR cDNA, \n\nfollowed by transfection and expression in mammalian cells. The analysis of reporter gene \n\ntransactivation with different dihydrotestosterone (DHT) concentrations was performed. \n\nN/C-terminal interactions for each AR mutant were analyzed using two-hybrid mammalian \n\nassay. PAIS mutations: p.Ser759Thr, p.Leu830Phe, p.Ile898Phe mutations showed \n\ntransactivation activity higher than 20% in physiological hormone concentration. In the \n\nN/C interaction assays, the p.Ile898Phe revealed a complete disruption of N/C interaction at \n\nall hormone concentrations; the p.Ser759Thr and p.Leu830Phe showed positive response \n\nwith increasing DHT. CAIS mutations: p.Leu768Val revealed a complete disruption of AR \n\naction; p.Gln798Glu and p.Cys806Phe mutations studied separately revealed responses to \n\nDHT induction similar to Mild and PAIS, respectively. However, when analyzed together, \n\ntransactivation activities lower than 10% in physiologic hormone conditions were observed, \n\nconsistent to CAIS phenotype. The p.Pro904Arg showed reduced transcriptional activity \n\nand abolished response in N/C terminal interaction, compatible with CAIS. We conclude \n\nthat the functional analysis of the AR could elucidate the molecular mechanisms associated \n\nwith each case of AIS, and may provide a basis for response to treatment in each particular \n\ncase. \n\n \n\n \n\n \n\n \n\n\n\n28 \n \n\nIntroduction \n\n \n\nThe androgen insensitivity syndrome (AIS) is clinically characterized by impaired \n\nvirilization in 46,XY individuals. The phenotype associated with AIS can range from mild \n\nAIS (MAIS) to complete AIS (CAIS). MAIS is characterized by gynecomastia and in- or \n\nsubfertility in phenotypically male individuals. Partial AIS (PAIS) may present with \n\npredominantly male development or ambiguous genitalia (AG) or even with predominantly \n\nfemale external genitalia with clitoromegaly and/or posterior labial fusion and development \n\nof breast and pubic hair. On the other hand, the most severe form known as complete AIS \n\n(CAIS) results in female external genitalia, sparse to absent pubic and axillary hair and \n\nnormal female breast development (3, 14, 19, 23, 24, 28). \n\nAIS can be caused by a de novo mutation or an inherited maternal mutation in the \n\nandrogen receptor (AR) gene. The AR gene is localized on the X-chromosome at Xq11-12 \n\nregion and mutations can be transmitted with an X-chromosomal recessive inheritance. The \n\nAR gene has eight exons and seven introns distributed in more than 186 kb. Within exon 1, \n\nencoding for the N-terminal region involved in transactivation of the receptor, there are two \n\npolymorphic regions. The first is a poly-Gln region which can range from 9 to 36 residues \n\nand the second is a poly-Gly region which ranges from 10 to 27 residues, in different \n\npopulations (3, 15, 27, 28). Variations on the number of repeats can be associated with \n\ndifferent conditions, for instance, a very long Gln-stretch causes spino-bulbar muscular \n\natrophy (40). \n\nThe AR protein contains approximately 920 amino acid residues with molecular \n\nweight of about 110 kDa (1, 13, 28). The AR is a nuclear receptor (NR) that belongs to the \n\nsuperfamily of ligand-activated transcription factors. Important functions can be attributed \n\nto AR in male development such as muscular and male genitalia development, voice \n\ndeepening and spermatogenesis. Therefore, impaired or increased AR activity can be \n\nassociated to AIS or prostate cancer, respectively (1, 2, 27). \n\nSimilarly to other members of the NR superfamily, the AR exhibits three basic \n\nfunctional domains, which are a variable amino-terminal domain (NTD), a conserved DNA \n\n\n\n29 \n \n\nbinding domain (DBD) and a conserved ligand binding domain (LBD). Between DBD and \n\nLBD there is a flexible linker, the hinge region (1, 3, 16, 25).  \n\nThe NTD (residues 1-538) is involved in the transactivation through interaction with \n\ntranscriptional machinery (1, 25, 30). This domain also harbors a ligand independent \n\nactivation function 1 (AF-1) which is the major activation domain for the AR. In the same \n\nregion, there are FXXLF and WXXLF residues (where F is phenylalanine, L is leucine, W \n\nis tryptophan and x is any amino acid), which are important for N/C-terminal interaction \n\nand hormone-receptor complex stabilization (1, 5, 7, 27).  \n\nThe DBD (residues 539-628) contains of two zinc fingers which are able to \n\nrecognize and bind to specific DNA sequence (5, 11, 16, 25). The hinge region (residues \n\n629-669) allows the nuclear translocation, receptor mobility, DNA binding and \n\ntransactivation (3, 5, 31). The LDB (residues 670-920) contains 11 helices responsible for \n\nthe organization of the ligand-binding pocket formed by helices 3, 4, 5, 7, 11 and 12 with \n\nalso beta-sheet preceding helix 6 (16). The LBD harbors an important and conserved \n\nregion, the ligand-depending activation function 2 (AF-2). The AF-2 is responsible for \n\nligand-dependent transcriptional activation and is formed by helice 3, 4, 5 and 12. Mutation \n\nor deletion of the AF-2 domain dramatically reduces transcriptional activation in response \n\nto a ligand. In contrast to other nuclear receptors, the AR preferentially interacts with the \n\nFQNLF in the NTD causing the N/C interaction, an important step toward the activation of \n\nAR. Damage in N/C interaction is associated with AIS, even when the hormone binding is \n\nnormal (5, 16, 27, 32, 34). \n\nIn the cytoplasm, the inactive AR form is complexed with heat shock proteins \n\nbefore binding to the hormone testosterone (T) or 5?-dihydrotestosterone (DHT). The heat \n\nshock proteins are dissociated from the AR after the hormone binding to LBD. The \n\ntranslocation to the nucleus leads to conformational changes, resulting in an AF-2 \n\nhydrophobic pocket formation. This hydrophobic pocket serves as a binding site for \n\ncoactivators and for the AR NTD interactions. The coactivators interaction increases AR \n\ntranscriptional activation (10, 32, 33).  \n\nMutations in the AR gene usually result in a decrease of ligand affinity, co-activator \n\ninteraction and also impaired DNA binding (33). However, in a substantial number of AIS \n\ncases, there is no clear correlation between AIS clinical phenotype and AR gene mutation \n\n\n\n30 \n \n\n(4, 12, 21). Nevertheless, there are more than 800 different AR mutations \n\n(http://androgendb.mcgill.ca) which have been described in more than 850 patients with \n\ndifferent AIS phenotypes (8). They are distributed in all AR domains, especially in LBD. \n\nThere is a predominance of missense mutations in the LBD correlated with a significantly \n\nhigher number of CAIS than PAIS cases (8, 9).  \n\nIn order to clarify the functional consequences of missense mutations in AR gene, \n\nwe investigated seven mutations, p.Gln798Glu+p.Cys806Phe, p.Leu768Val and \n\np.Pro904Arg associated with CAIS, p.Ser759Thr, p.Leu830Phe and p.Ile898Phe associated \n\nwith PAIS all located in the LBD. The combination of the new mutation p.Cys806Phe and \n\nthe well-known p.Gln798Glu was particularly found in one patient with CAIS. Five of \n\nthese variants have been previously described in Brazilian patients (22, 26, 29). In order to \n\nunderstand the functional properties of these mutations, the impact of each one on full \n\nlength AR transactivation capacity and on AR N/C-terminal interactions were investigated.  \n\n \n\nMaterial and Methods \n\n \n\nPatient descriptions \n\nPatient with p.Gln798Glu+p.Cys806Phe mutations: \n\nThis girl was referred to us with 13 years of age. She was born at term by normal \n\ndelivery after an uneventful pregnancy with a birth weight of 3,950 g. Inguinal hernias were \n\ndetected in the neonatal period and were surgically repaired when she was 2 months old. \n\nBilateral testes were found at inguinal herniorrhaphy, and both were removed when the \n\nchild was 16 months old. Estrogens had been prescribed five months before her first visit to \n\nour service. \n\nHer parents were unrelated, and family history was unremarkable. She had two \n\nnormal sisters aged 19 and 17 years and a younger 2.5-year-old brother. On physical \n\nexamination, her height was 166.2 cm and weight 80.3 kg. She had typical female external \n\ngenitalia and pubertal stage was B2P2. Hormonal evaluation revealed high levels of FSH \n\n(92.6 UI/L; normal range (NR): 1.5-12.4 UI/L) and LH (20.6 UI/mL; NR: 1.7-8.6 UI/mL) \n\nand prepubertal levels for total testosterone (1.41 nmol/L; NR:  9.92-28.11 nmol/L); her \n\nkaryotype was 46,XY.  \n\nhttp://androgendb.mcgill.ca/\n\n\n31 \n \n\nClinical data for patients with p.Ser759Thr, p.Leu768Val., p.Leu830Phe, \n\np.Ile898Arg and p.Pro904Arg mutations have been previously described (22, 26, 29). \n\n \n\nPlasmids \n\nAR expression plasmids \n\nAll mutations were introduced into the full-length AR expression vector (pSVAR0), which \n\nwas kindly provided by Dr. A. Brinkmann, from the University Hospital Rotterdam, \n\nRotterdam, NL University. Each point mutation was inserted by PCR based site directed \n\nmutagenesis with specific primers (Table 1). \n\nTable 1: Mutagenesis primers used in this study  \n\nPrimer                                       Sequence 5\u2019-3\u2019                 \n\nAR_p.Ser759Thr_sense: CTTCACCAATGTCAACACCAGGATGCTCTACTT \n\nAR_p.Ser759Thr_antissense: AAGTAGAGCATCCTGGTGTTGACATTGGTGAAG \n\nAR_p.Le768Val_sense: CTACTTCGCCCCTGATGTGGTTTTCAATGAGTA \n\nAR_p.Leu768Val_antissense: TACTCATTGAAAACCACATCAGGGGCGAAGTAG \n\nAR_p.Gln798Glu_sense: GAGTTTGGATGGCTCGAAATCACCCCCCAGG \n\nAR_p.Gln798Glu_antissense: CCTGGGGGGTGATTTCGAGCCATCCAAACTC \n\nAR_p.Cys806Phe_sense: CCCAGGAATTCCTGTTCATGAAAGCACTGCT \n\nAR_p.Cys806Phe_antissense: TAGCAGTGCTTTCATGAACAGGAATTCCAGT \n\nAR_p.Leu830Phe_sense: TTCTTTGATGAATTTCGAATGAACTAC \n\nAR_p.Leu830Phe_antissense: GTAGTTCATTCGAAATTCATCAAAGAA \n\nAR_p.Ile898Phe_sense: GAAATGATGGCAGAGTTCATCTCTGTGCAAGT \n\nAR_p.Ile898Phe_antissense: ACTTGCACAGAGATGAACTCTGCCATCATTTC \n\nAR_p.Pro904Arg_sense: ATCTCTGTGCAAGTGCGCAAGATCCTTTCTG \n\nAR_p.Pro904Arg_antissense:   CAGAAAGGATCTTGCGCACTTGCACAGAGAT \n\n\n\n32 \n \n\n \n\nMutagenesis primers were designed using GeneRunner v.3.05 (free software). \n\nIn brief, PCR mutagenesis was performed in two steps. Using pSVAR0 as template, \n\nin the first step AR_LBD644s (5\u00b4-GAGGCTTCCAGCACCACCA-3\u00b4) was used as sense \n\nprimer together with each respective mutagenesis antisense primer. The second \n\namplification was performed with the respective mutagenesis sense primer and pSV0seq_as \n\n(5\u2019- TGATAGGCAGCCTGCACCTGA -3\u2019). Both amplicons were gel purified, combined, \n\nannealed and amplified in a third PCR using the primer pair AR_LBD644s - pSV0seq_as. \n\nMutant amplicons were double digested with Tth111 I/Pst I and subcloned into pSVAR. All \n\ninserts and their cloning borders were verified by sequencing.  \n\n \n\nTwo hybrid constructs \n\n \n\nAR N/C interaction was analyzed using the mammalian two-hybrid assay kit \n\n(Stratagene, La Jolla, CA). In order to generate mammalian two-hybrid clones containing \n\nthe GAL4 DNA binding domain fused to AR618-920, the AR LBD618-920 was amplified using \n\nthe primer pair AR1823s_BamH I (5\u2019- TGGATCCCGGAAATGTTATGAAGCAG -3\u2019) \n\nand pSV0seq_as using wt or mutant full length AR as template. Amplicons were double \n\ndigested by BamH I and Pst I and subcloned into pCMV_BD bait vector (Stratagene). The \n\nvector pAD_NTD1-536 containing the GAL4 activation domain in fusion to the N-terminal \n\ndomain of AR (aa 1-536) was previously described in (32).   \n\n \n\nLuciferase genes  \n\n \n\nThe p(ARE)2TATA-Luc vector which contains two androgen responsive elements \n\n5\u2019 of the TATA-box preceding the firefly luciferase gene was a kind gift of Dr. G. Jenster \n\nfrom Josephine Nefkens Institute, Erasmus MC (Rotterdam, NL). The pFR-Luc vector \n\n(Stratagene, La Jolla, CA) contains a synthetic promoter with five tandem repeats of yeast \n\nGAL4 binding sites which control the expression of the firefly luciferase gene and served \n\nas a reporter gene in mammalian two hybrid assays. Plasmid phRGTK contains a \n\n\n\n33 \n \n\nconstitutive active Renilla luciferase reporter gene used to normalize transfection efficiency \n\nin Dual Luciferase Assays (Promega). \n\n \n\nTransient Transfections of Full length AR \n\n \n\nThe Chinese hamster ovary (CHO) cells were used to express the wild type and \n\nmutant AR proteins. Transfection experiments were performed as previously described \n\n(31). In brief, 80,000 cells/well were cultured overnight in 24-well plates with Dulbecco\u2019s \n\nmodified Eagles Medium/Nutrient Mixture F-12 Ham (DMEM/F12, Sigma) supplemented \n\nwith 10% dextran charcoal-stripped fetal calf serum under 5% CO2 at 37\u00b0C. After initial \n\nincubation, 30 ng wt-AR or mutant plasmid DNAs were co-transfected with 200 ng \n\np(ARE)2TATA-Luc and 5 ng phRGTK using 0.5 \u00b5l FuGENE HD (Promega Corp., \n\nMadison, WI). Five hours after transfection, 0\u2013100 nmol/l DHT were added in each well. \n\nThe luciferase activity was determined 18 h after hormone induction, using a Dual \n\nLuciferase assay (Promega Corp., Madison, WI) and normalized to transfection efficiency. \n\nFor comparison of experiments performed at different days, we set the transactivity of wt-\n\nAR at 10 nmol/l DHT as 100%. Relative luciferase units (RLU) of other samples assayed at \n\nthe same time were expressed relative to this value. For statistical analysis, all transfections \n\nwere performed in triplicate and at least three independent experiments were carried out. \n\n \n\nTwo hybrid assays \n\n \n\nN/C interaction assays have been described in detail previously (32). In brief, CHO \n\ncells were cultured and seeded in 24-well plates as described above. 100 ng pBD-LBD618-\n\n920 (bait, wild type or mutant) and 100 ng of pAD-NTD1-536 (prey) were co-transfected with \n\n200 ng pFR-Luc (reporter gene) and 10 ng phRGTK per well using 1.0 ?l FuGENE HD \n\n(Promega). Five hours post-transfection, LBDs were activated by adding the indicated \n\namount of DHT (0\u2013100 nM). The luciferase activities were measured 18 h after hormonal \n\ninduction using the Dual Luciferase assay system (Promega). As for full-length assays, the \n\nluciferase activity of wild type NTD/LBD interaction at 10 nmol/l DHT was set to 100%. \n\nTransfection efficiency was normalized by Renilla luciferase. For statistical analysis, all \n\n\n\n34 \n \n\ntransfections were carried out in triplicate and at least three independent experiments were \n\nperformed. \n\n \n\nWestern Blots Analysis \n\n \n\nFor protein expression analysis 300,000 CHO cells were grown in six well culture \n\nplates overnight. Cells were transfected using 1 ?g p(ARE)2 TATA-Luc plasmid, 150 ng \n\nwild type or mutant AR plasmid, 25 ng phRGTK and 3.35 ?l Fugene HD reagent per well. \n\nAfter 16 h, cells were washed twice with cold PBS and lysed in 250 ?l M-PER lysis buffer \n\n(Pierce, Rockford, IL) including complete proteinase inhibitor cocktail (Roche, Mannheim, \n\nGermany) on ice for 5 min. Cells were scraped and collected for Western blot analysis. \n\nProtein concentration was estimated by Bio-Rad protein assay (Bio-Rad, Richmont, CA). \n\nThe remainder of protein was dissolved in SDS sample buffer and denatured by heating at \n\n95\u00b0C for 10 minutes followed by SDS-PAGE.  \n\nFull-length AR and NTD were detected with primary antibody anti AR F39.4.1 \n\n(Innogenex, San Ramon, CA) diluted 1:500. GAL4-LBD fusion proteins were detected \n\nwith primary antibody AR-C19 (sc-815, Santa Cruz Biotechnology Inc.) diluted 1:200. \n\nActin was detected using anti-actin antibody A2066 (Sigma) diluted 1:1000. Signals were \n\nvisualized using the corresponding conjugated anti-mouse or anti-rabbit secondary antibody \n\napplying the Western Lightning Chemiluminescent Reagent Plus (PerkinElmer, Boston, \n\nMA) and a Fusion SL chemiluminescent imager (Vilbert Lourmat). \n\n \n\nResults: \n\nIn order to analyze the effect of AR mutant proteins on AR transactivation capacity \n\nassociated with CAIS and PAIS phenotype, full-length AR plasmids were co-transfected \n\nwith the firefly luciferase reporter plasmid p(ARE)2TATA-Luc in CHO cells. Expression of \n\ncomparable amounts of wild-type (wt) and mutants either for full-length AR proteins (Fig. \n\n1A) or Gal4-LBD fusion protein constructions (Fig. 1B-D) were confirmed by Western \n\nblotting. \n\n \n\n \n\n\n\n35 \n \n\nFull Length AR Transactivation and N/C interactions in PAIS related mutations \n\n \n\n The mutations associated to PAIS phenotype that have been tested were \n\np.Ser759Thr, p.Leu830Phe and p.Ile898Phe. In transactivation assays, all three mutations \n\nrevealed low response activities at low hormone concentrations reaching approximately \n\n27% (t-test, P<0,001), 30% (t-test, P=0,002) and 22% (t-test, P<0,001) of the wt at 1.0 nM \n\nDHT, respectively. At high and supraphysiological hormone concentration the responses \n\nreached 80% (t-test, P<0,0001) and 62% (t-test P<0,0001) for p.Ser759Tre and \n\np.Ile898Phe, respectively, at 100 nM DHT; whereas it was totally recovered for \n\np.Leu830Phe (t-test P<0,7263) (Figure 2A).  \n\nIn N/C interaction analyses, the p.Ser759Thr mutation showed significantly reduced \n\nresponses at all hormone concentrations. Transactivation of the reporter gene was almost \n\nundetectable at low DHT concentrations (0.1-1 nM) showing gradually higher responses \n\nwith the increase in DHT concentration. It reached only 50% (t-test, P<0,0001) at a \n\nsupraphysiological DHT concentration(100 nM) (Fig 2B).Similarly, the response of the \n\nreporter gene for p.Leu830Phe at low hormone concentrations (0.1-1.0 nM) was \n\nundetectable. However, it was totally recovered at 3.3 nM DHT and it showed a \n\ntranscriptional activity 2.5 times higher than the wt in the presence of 100 nM DHT   \n\n(Figure 2B).  \n\n  Conversely, p.Ile898Phe did not show any detectable activity of reporter gene in \n\nthe N/C interaction assay, indicating that in this case N/C interation was completely \n\nabolished (Figure 2B). \n\n \n\nFull Length AR Transactivation and N/C interactions in CAIS related mutations \n\n \n\nThe mutations associated to CAIS phenotype that have been tested were \n\np.Leu768Val and p.Pro904Arg. \n\nIn the experiment using full-lengh AR the reporter gene activation by p.Leu768Val \n\nmutant was undetectable from 0.1 to 3.3 nM DHT and reached only 36% (t-test, P<0,0001) \n\nat 100 nM (Figure 3A). Conversely, p.Pro904Arg showed a better response to DHT \n\nstimulus presenting 20% (t-test, P<0,0001) of the reporter gene activation at 1.0 nM (Fig. \n\n\n\n36 \n \n\n3A). At high and supraphysiological hormone concentrations the response was \n\napproximately that of the wt. However, a drastic effect upon the reporter gene activation is \n\nobserved for both mutations in N/C interaction assays. Whereas p.Leu768Val did not show \n\nany response even in supraphysiological hormone concentration, p.Pro904Arg showed \n\napproximately 30% (t-test, P=6934) of the reporter gene activation only at 100 nM DHT. \n\nThose results indicate that N/C interaction was severely disrupted by both mutations, \n\n(Figure 3B). \n\n \n\nFull Length AR Transactivation and N/C interactions for p.Gln798Glu+p.Cys806Phe \n\n \n\nThe novel p.Cys806Phe AR mutation was identified in association with \n\np.Gln798Glu,  a well known AR mutation. Therefore, full-length and N/C interaction \n\nexperiments were performed for individual and combined mutations . Individually, \n\np.Gln798Glu retained 80-90% (t test, P=0,0356) the capacity of transactivating reporter \n\ngene expression in both full-legth and N/C interaction experiments (Figure 4A, B); \n\nwhereas, p.Cys806Phe showed less than 30% activity (t-test, P<0,0001) at 1.0 nM DHT \n\nand recovered to almost 95% (t-test, P<0,0001) at 100 nM in the full-length experiment \n\n(Figura 4C). Similarly to the effect observed for p.Leu830Phe in the N/C interaction assay, \n\np.Cys806Phe also showed increasing activity of the reporter gene as hormone concentration \n\nincreased being almost 3 times higher than the wt at 100 nM (Figura 4D) with a drastic \n\neffect upon the reporter expression at 1.0 nM. When those two mutations were combined in \n\none construct the capacity of activating the reporter gene expression at 1 nM DHT \n\nremained below 10% in both assays (Figure 4E, F). For higher DHT concentrations, the \n\ncombination p.Gln798Glu+p.Cys806Phe showed increased response although remained \n\nbelow 80% (t-test, P>0,0031) at 100 nM DHT in the full-lengh assay. Those results indicate \n\na synergistic effect since a less severe effect was individually observed for those mutations \n\neither in low or in high DHT concentrations. However, the results under high DHT \n\nconditions (10-100 nM) in the N/C interaction assays followed that of p.Cys806Phe \n\nreaching 2.5 times the wt transactivation capacity (Figure 4F).  \n\n  \n\n \n\n\n\n37 \n \n\nDiscussion \n\n \n\nThe androgen insensitivity syndrome is described as a dysfunction in the AR, which \n\ncan be associated with a mutation in AR gene or due to unknown mechanisms (12, 14, 15, \n\n21). Thus, patients with AIS are initially screened for AR mutations by AR gene \n\nsequencing. In this study we describe functional activities of six missense mutations and \n\none combination of two missense mutations, all of them located in the LBD region, three \n\npoint mutations were associated with PAIS, other mutations were associated with CAIS \n\nphenotype. \n\nPAIS mutations p.Ser759Thr, p.Leu830Phe and p.Ile898Phe showed increasing  \n\ntransactivation capacities on the reporter gene with increasing hormone concentration. At \n\nphysiological hormone concentration (1.0 nM DHT), the response was lower than 40%, \n\nwhich indicated PAIS classification. However, they differed in the N/C interaction assays. \n\nAR p.Ser759Thr was previously described in a patient with PAIS by Takahashi et al.  (47). \n\nIn our study, the patient with p.Ser759Thr presented micropenis and hormone dosages \n\nsuggesting PAIS phenotype, as described by Tobo et al. (29). Transactivation assay with \n\nfull-length AR cDNA with p.Ser759Thr showed a reduced activity at low hormone \n\nconcentrations (0.1-1 nM) that reached 80% at high and supraphysiological levels of DHT. \n\nThe residue Ser759 is in the loop between helix 5 and helix 6 of AR protein. As this region \n\nis part of the ligand-binding pocket, alterations might be associated with an impairment of \n\nN/C interaction (8, 32, 33, 36, 39). This is supported by N/C interaction data presented here \n\nwhere loss of transactivation ability at low to physiological hormone concentrations (0.1-1 \n\nnM) was demonstrated, whereas a moderate rescue at high to supraphysiological levels \n\n(3.3-100 nM) reaching only 50% of the wt activity. Differently to p.Ser759Tre, the \n\np.Ile898Phe revealed a complete disruption in N/C interaction at all hormone \n\nconcentrations indicating a CAIS phenotype. However, this mutation was described in a \n\nfamily with severe PAIS (20) suggesting that other interactions could be involved in AR \n\nactivity in this case. The residue Ile898 is located at the end of helix 11, near helix 12. This \n\nregion is conserved in steroid receptors due to the important role in the protein-protein \n\ninteractions performed with AF-2 (21, 25, 32, 37). \n\n\n\n38 \n \n\nA quite different profile was observed for p.Leu830Phe and p.Cys806Phe mutants. \n\nDespite low activity in the N/C interaction experiment at low to normal hormone values \n\n(0.1-1 nM), they equal the wt with high hormone values (around 3.3 nM) and surprisingly \n\nat high to supra physiological DHT concentrations transactivation activities were almost \n\ntwo times that of the wild type. The mechanism of this unusual hormone response is not \n\nknown yet. Similar result was obtained with the CAIS related double mutant \n\np.Gln798Glu+p.Cys806Phe. Likewise, our group had observed similar patterns in N/C \n\ninteraction experiments with p.Arg840His mutation (41) as well as with p.Arg840Cys \n\n(unpublished results). Szafran et al. (42) using HeLa cells also report absence of N/C \n\ninteraction at low (0.2 nM) testosterone concentrations and increased N/C interaction at 20-\n\n200 nM T for p.Arg840Cys AR mutant. This effect was first reported by Wong et al. (33) \n\nwho described an increased N/C interaction and an increased TIF2 coactivation at high \n\nhormone concentrations for PAIS mutation p.Phe826Leu. Independent assays using two \n\ndifferent promoters and three different ligands were performed to test p.Phe826Leu and \n\nsimilar results were obtained (33). Those results differed from ours in that p.Cys806Phe, \n\np.Leu830Phe and p.Arg840His/Cys mutations led to a loss of N/C interaction at low \n\nhormone concentrations and switch to an increased N/C interaction at high hormone \n\nconcentrations, whereas p.Phe826Leu always led to an increased N/C interaction, at both \n\nlow and high hormone concentrations. Nevertheless, these results indicated that some \n\nresidues could impact AF2 function despite the location outside AF2 or ligand binding \n\npocket. Residues Arg826, Leu830 and Arg840 are located on helix 9 and are part of \n\nbinding function 3 (BF-3), a concave surface topographically adjacent but distinct from \n\nAF2, that allosterically regulates coactivator binding (43). Residue Cys806 is located on \n\nhelix 8, just below Arg840 on helix 9 (Figure 5). Substitution of the cysteine by a more \n\nbulky phenylalanine at residue 806 may disturb the BF-3 conformation; consequently, it \n\nmay destabilize coactivator binding. Crystal structures of AR-LBDs bound to co-activator \n\npeptides differ from those without bound peptides indicating that structural rearrangements \n\noutside the AF2 pocket in different residues located at BF-3, for instance, Phe826 and \n\nArg840, possibly transmit their effect though residues located at the boundary between \n\nthem (43). Leu830 divides BF-3 and the conformation of the side chain is responsible for \n\nfurther dissecting of BF-3 into 2 sockets (43). The more bulky phenylalanine residue may \n\n\n\n39 \n \n\nimpact on this BF-3 dissection thereby may influence AF2 peptide binding in the BF-3/AF2 \n\ncommunication. Hormone insensitivity at low steroid concentrations caused by \n\np.Cys806Phe, p.Leu830Phe and p.Arg840His/Cys points to an interference with \n\nchaperone/cochaperone/immunophilin interaction. Steroid hormone receptor amino acid \n\nsequence alignments identified six residues, including Cys806 and Arg840 that are \n\nconserved among the FKBP52-regulated AR receptors, glucocorticoid receptor (GR) and \n\nprogesterone receptor (PGR), but differ in the FKBP52-insensitive mineralocorticoid \n\nreceptor (MR) (44). The alteration p.Cys806Tyr was described previously, associated with \n\nPAIS (38). Interestingly, functional assays in yeast demonstrated an increased dependence \n\non FKBP52 for function of AR mutation p.Cys806Tyr (44). Grosdidier et al. (37) described \n\nthe same effect on N/C interaction with the CAIS associated alterations p.Asn833Arg and \n\np.Arg840Ala. These results can be associated with many events in AR action, such as \n\ntranscriptional activity and alteration in co-activator binding. Therefore, such interesting \n\neffects suggest this region as a special place for future investigations (37). \n\nTwo mutations associated to CAIS phenotype have been investigated. The AR \n\np.Leu768Val resulted in a severe effect upon transcriptional activity in both assays showing \n\na weak transcriptional activity only at supraphysiological hormone concentrations in the \n\nfull-length cDNA experiment. The residue Leu768 is located in the loop between helixes 5 \n\nand 6. Alterations in this region can present an important role in conformation of N/C \n\ninteraction or a disruption in AF2, resulting in the impairment in the hormone binding (16, \n\n17, 23). Helsen et al. (11) described the residue Pro766 involved in DBD-LBD interaction. \n\nThis alteration was found in a patient with amenorrhea and testes in labia majora (23). \n\nOther mutations have been described in the same residue, such as the CAIS associated \n\nmutation p.Leu768Pro and PAIS associated mutation p.Leu768Met (8, 17). The amino acid \n\nLeu768 is conserved in other hormone receptors (36). Due to the localization and \n\nconservation of Leu768, alteration in this residue can result in damage of AR ligand-\n\nbinding pocket stabilization and also in the binding of co-regulators (23, 38). The other \n\nCAIS related mutation studied here was p.Pro904Arg. Residue Pro904 is highly conserved \n\namong steroid receptors (45, 46). CAIS mutations p.Pro904His and p.Pro904Ser have been \n\npreviously described in this residue (21, 32). AR p.Pro904Arg is located at the end of helix \n\n12 which together with helix 3, 4 and 5 forms AF2. A response as low as 20% at \n\n\n\n40 \n \n\nphysiologic hormone concentration (1.0 nM DHT) was observed in the full-length \n\nexperiment whereas it equaled the wt at high and supraphysiological hormone \n\nconcentrations. However, the transcriptional activity in the N/C interaction assay did not \n\nexceed 40% even in supraphysiological hormone concentrations. The residue Pro904 has \n\nnot a significant contact with ligand in LBD; however alterations in Pro904 might affect the \n\nreconstitution of AF2 and the sealing of the ligand-binding pocket (21, 30). \n\nFinally, the combination p.Gln798Glu+p.Cys806Phe were identified in a girl with \n\nCAIS. To understand the effect of this mutation, we tested each separately and the \n\ncombination. At physiologic hormone concentration (1.0 nM DHT) p.Gln798Glu, \n\np.Cys806Phe and AR p.Gln798Glu+p.Cys806Phe showed a transcriptional activation of the \n\nreporter gene showed a residual activity of 77%, 22% and >10%, respectively, in both full-\n\nlength cDNA and N/C interaction experiments. At high hormone concentration (>10 nM of \n\nDHT), these mutations recovered the activity reaching ? 80% in the full-length cDNA \n\nassays. In N/C assays, those mutations presented increasing transactivation activity \n\nreaching almost 3 times the wt, except p.Gln798Glu that did not exceed the wt activity. \n\nMutation AR p.Gln798Glu was previously investigated in vitro, although using different \n\nreporter genes and cell lines (12, 16). Those results together with ours indicate that \n\nmutations in residue Gln798 seem not to be very harmful since they were described \n\nassociated with MAIS, PAIS and prostate cancer (13, 14, 15). However, it seems to exert a \n\nsynergistic negative effect on the AR transcriptional ability when combined in the \n\np.Gln798Glu+p.Cys806Phe double mutant since this function was slightly more \n\ncompromised than in each mutation separately. The N/C-terminal interaction of AR \n\np.Gln798Glu+p.Cys806Phe and AR p.Cys806Phe at low to normal hormone concentrations \n\nwas abolished whereas, at supra physiologic hormone concentration they showed enhanced \n\nN/C-terminal interaction, similar to AR p.Leu830Phe. Mutation p.Gln798Glu had no \n\nsignificant impact on N/C interaction, indicating that mutation p.Cys806Phe is the more \n\nsevere mutation mostly responsible for the phenotype.  \n\nIn conclusion, we described six mutations associated with PAIS and CAIS \n\nphenotypes. Dysfunctions of the mutations were confirmed by in vitro assays. Functional \n\nanalysis can clarify the mechanism of AR action and can be very helpful for choosing the \n\nappropriate therapy for the patient as well. Although many studies on the AR protein have \n\n\n\n41 \n \n\nbeen described in the literature, new results can support new strategies aiming the \n\nidentification of the real AR mutation effect in the phenotype of each patient. \n\n \n\nAcknowledgements \n\n \n\nAuthors would like to thank Mr. Wanderley Pedroso da Gra\u00e7a from Laborat\u00f3rio \n\nNacional de Bioci\u00eancias, CNPEM/ABTLuS sequencing facility and also Mrs. Alessandra \n\nOliveira from Laborat\u00f3rio Multiusu\u00e1rio, CBMEG, UNICAMP. \n\nThe authors address a special thanks to Mrs. Cristiane dos Santos Cruz Piveta \n\nfor technical support. This work was supported by grants #  2009/08320-9 (MPM) and \n\nscholarships # 2008/01964-5 (RJP) from Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o \n\nPaulo (FAPESP). This work was also supported by grants from Coordena\u00e7\u00e3o de \n\nAperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) to RJP and Conselho \n\nNacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq - Brasil) to \n\nGGJ and MPM. The functional studies were in part supported by the University of L\u00fcbeck \n\n(Focus Programme support to OH and RW) as well as by funding from the European Union \n\nunder the 7\nth\n\n framework programme (EuroDSD, 201444) to OH and RW. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n42 \n \n\nFigures: \n\n \n\n \n\n \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\nFigure 1. Western blot analysis of wt and mutant AR. (A) Full-length AR wt and mutants \n\nwere incubated with the anti-AR antibody F39.4.1. Detection of actin protein by actin \n\nantibody was performed on the same membrane. Lanes 1-7: p.Pro904Arg, p.IleI898Phe, \n\np.Leu830Phe, p.Cys806Phe, p.Leu768Val, p.Ser759Thr and wt; lane 8: non-transfected \n\nCHO cells. (B-D) GAL4-DBD/AR-LBD fusion constructs detected with AR-C19 antibody; \n\n(B) lane 1: non-transfected CHO cells, lanes 2-4: wt AR fusion protein incubated with 0 \n\nnM, 1 nM and 10 nM DHT and lanes 5-7: p.Cys806Phe fusion protein incubated with 0 \n\nnM, 1 nM and 10 nM DHT. (C) lane 1: non-transfected CHO cells, lanes 2-4: wt AR-LDB \n\nfusion protein incubated with 0 nM, 1 nM and 10 nM DHT and lanes 5-7: p.Leu830Phe \n\nfusion protein incubated with 0 nM, 1 nM and 10 nM DHT. (D) lane 1: non-transfected \n\nCHO cells, lanes 2-3: wt AR-LDB fusion protein incubated with 0 nM and 10 nM DHT and \n\nlanes 4-5: p.Ser597Thr fusion protein incubated with 0 nM and 10 nM DHT, lanes 6-7: \n\np.Ile898Phe fusion protein incubated with 0 nM and 10 nM DHT, lanes 8-9: p. Leu768Val \n\nfusion protein incubated with 0 nM and 10 nM DHT and lanes 10-11: p.Pro904Arg fusion \n\nprotein incubated with 0 nM and 10 nM DHT. Detection of ?-actin was performed on the \n\nsame membrane as a loading control for the experiment. \n\n \n\n \n\n \n\n? -actin \n\nAR \n\n?-actin \n\nAR-LBD \n\n1 6 7 4 5 3 2 \n\n \n\n? -actin \n\nAR-LBD \n\n1 6 7 4 5 3 2 8 9 10 11 \n\n?-actin \n\nAR-LBD \n\n1 6 7 4 5 3 2 \n\nA B \n\nC \nD \n\n \n\n\n\n43 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 2. Transcriptional activity of the full-length (A) and N/C interaction (B) of PAIS \n\nrelated mutations. In A, CHO cells were transfected with the androgen-responsive firefly-\n\nluciferase reporter p(ARE)2 TATA-Luc, the Renilla luciferase plasmid phRGTK and full-\n\nlength AR constructs (pSVAR_wt and mutants: pSVAR_p.Ser759Thr, \n\npSVAR_p.Leu830Phe and pSVAR_p.Ile898Phe. In B, CHO cells were transfected with the \n\nbait vector: pBD_LBD_wt or mutants: p.BD_LBD_p.Ser759Thr, pBD_LBD_p.Leu830Phe \n\nand p.BD_LBD_p.Ile898Phe, the target fusion construct pAD_NTD, the firefly reporter \n\ngene pFR_Luc and the constitutively expressed Renilla luciferase phRGTK. The cells were \n\ntreated with indicated amount of hormone five hours after transfection. Transfection \n\nefficiencies were normalized using the Dual Luciferase Assay kit. The activity of the wt \n\nconstruct at 10 nM DHT was set to 100%. The statistical analysis was performed with data \n\nof 3 independent experiments in triplicates with + 1 SD error bars. RLU: relative luciferase \n\nunits. \n\n WT \np.Ser759Thr \np.Leu830Phe \np.Ile898Phe \n\nWT \np.Ser759Thr \np.Leu830Phe \np.Ile898Phe \n\nA \n\nB \n\nnM[DHT] \n\nnM[DHT] \n\n\n\n44 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 3. Transcriptional activity of full-length (A) and N/C interaction (B) of CAIS \n\nrelated mutations. In A, CHO cells were transfected with the androgen-responsive firefly-\n\nluciferase reporter p(ARE)2 TATA-Luc, the Renilla luciferase plasmid phRGTK and full-\n\nlength AR constructs: pSVAR_wt and mutants: pSVAR_p.Leu768Val, \n\npSVAR_p.Pro904Arg. In B, CHO cells were transfected with the bait vector: \n\npBD_LBD_wt or mutants: pBD_p.Leu768Val, pBD_p.Pro904Arg, the target fusion \n\nconstruct pAD_NTD, the firefly reporter gene pFR_Luc and the constitutively expressed \n\nRenilla luciferase phRGTK The cells were treated with indicated amount of hormone five \n\nhours after transfection. Transfection efficiencies were normalized using the Dual \n\nLuciferase Assay kit. The activity of the wt construct at 10 nM DHT was set to 100%. The \n\nstatistical analysis was performed with data of 3 independent experiments in triplicates with \n\n+ 1 SD error bars. RLU: relative luciferase unit. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n WT \n\n p.Leu768Val \n\np.Pro904Arg \n\n WT \n\n p.Leu768Val \n\np.Pro904Arg \n\nnM[DHT] nM[DHT] \n\n\n\n45 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 4. Transactivation of full-length and N/C interaction and of p.Gln798Glu, \n\np.Cys806Phe and double mutant p.Gln798Glu+p.Cys806Phe.  In A, C and E CHO cells \n\nwere transfected with androgen-responsive firefly-luciferase p(ARE)2TATA-Luc, the \n\nRenilla luciferase plasmid phRGTK and full-length  wt AR or AR_p.Gln798Glu, \n\nAR_p.CysC806Phe and AR_p.Gln798Glu+p.Cys806Phe. In B, D and F, CHO cells were \n\ntransfected with pBD_LBD_wt or pBD_LBD_p.Gln798Glu, pBD_LBD_p.CysC806Phe, \n\npBD_LBD_p.Gln798Glu+p.Cys806Phe,  pAD_NTD fusion constructs, pFR_Luc and the \n\n WT \n\n p.Gln798Glu \n\n WT \n\n p.Cys806Phe \n\n WT \n\n p.Cys806Phe \n\n WT \n\n p.Gln798Glu+p.Cys806Phe \n\n WT \n\n p.Gln798Glu+p.Cys806Phe \n\nnM[DHT] \n\nR\nLU\n\n \n\nR\nLU\n\n \nR\n\nLU\n \n\nR\nLU\n\n \nR\n\nLU\n \n\nR\nLU\n\n \n\n WT \n\n p.Gln798Glu \n\nA B \n\nC D \n\nE \n\nF \n\nnM[DHT] \n\nnM[DHT] nM[DHT] \n\nnM[DHT] \n\n \n\nnM[DHT] \n\n \n\n\n\n46 \n \n\nphRGTK (Renilla luciferase). Five hours after transfections, cells were treated with \n\nindicated concentration of DHT. Transfection efficiencies were normalized using the Dual \n\nLuciferase Assay kit. The activity of the wt or mutant constructs at 10 nM DHT was set to \n\n100%. At least three independent experiments were performed in triplicates, error bars + 1 \n\nSD. RLU: relative luciferase units. \n\n \n\n \n\nFigure 5: Simplified model representation of AR LBD structure. A, helix 8 showing the \n\nresidue Cysteine 806 in orange; and, the helix 9 showing residues Phenylalanine 826 in red, \n\nLeucine 830 in purple and Arginine 840 in blue. B, Solid-surface representation of AR \n\nLBD in green showing the residues Cys 806, Phe 826, Leu 830 and Arg 840. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPhe826 \n\nLeu830 \n\nArg840 \n\nCys806 \n\nHELIX 9 \n\nA B \n\n\n\n47 \n \n\nReferences \n\n1. Aranda A. N. A., Pascual A., Biome, I. D. I. (2001). Nuclear Hormone Receptors and Gene \n\nExpression, 81(3):1269\u20131304. \n\n2. Ahmed S. F., Bashamboo, a, Lucas-Herald, McElreavey, K. (2013). Understanding the \n\ngenetic aetiology in patients with XY DSD. British medical bulletin, 106, 67\u201389.  \n\n3. Brinkmann A. O. (2001). Molecular basis of androgen insensitivity. Molecular and Cellular \n\nEndocrinology, 179:105-109. \n\n4. Brinkmann A. O. (2011). Molecular mechanisms of androgen action. Androgen Action. (F. \n\nSaatcioglu, Ed.), Methods in molecular biology 776. pp. 3-24. \n\n5. Clinckemalie L., Vanderschueren D., Boonen, S., Claessens, F. (2012). The hinge region in \n\nandrogen receptor control. Molecular and cellular endocrinology, 358(1):1\u20138.  \n\n6. Bevan C. L., Brown B. B., Davies H. R., Evans B. A., Hughes I. A., Patterson M. N. \n\n(1996). Functional analysis of six androgem receptor mutation identified in patients with \n\npartial androgen insensitivity syndrome. Human Molecular Genetics, 5:265-273. \n\n7. Est\u00e9banez-Perpi\u00f1\u00e1 E., Arnold, L., Nguyen P., Rodrigues E. D., Mar, E., Fletterick, R. J. \n\n(2007). A surface on the androgen receptor that allosterically regulates coactivator binding. \n\nProceedings of the National Academy of Sciences of the United States of America, \n\n104(41):16074\u20139.  \n\n8. Gottlieb B., Beitel L. K., Wu J. H., Trifiro M. (2004). The androgen receptor gene \n\nmutations database (ARDB): 2004 update. Human Mutation, 23:527-533. \n\n9. Hannema S. E., Scott I. S., Hodapp J., Martin H., Coleman N., Schwabe J. W., Hughes I. A. \n\n(2004). Residual activity of mutant androgen receptors explains wolffian duct development \n\nin the complete androgen insensitivity syndrome. Journal Clinical Endocrinology and \n\nMetabolism, 89:5815-22. \n\n10. He B. &amp; Wilson E. M. (2002). The NH(2)-terminal and carboxyl-terminal interaction in the \n\nhuman androgen receptor. Molecular genetics and metabolism, 75(4), 293\u20138.  \n\n11. Helsen C., Kerkhofs S., Clinckemalie L., Spans L., Laurent M., Boonen, S., Claessens F. \n\n(2012). Structural basis for nuclear hormone receptor DNA binding. Molecular and cellular \n\nendocrinology, 348(2):411\u20137.  \n\n\n\n48 \n \n\n12. Hiort O., Holterhus P. M., Horter T., Schulze W., Kremke B., Bals-Pratsch M., Sinnecker \n\nG. H., et al. (2000). Significance of mutations in the androgen receptor gene in males with \n\nidiopathic infertility. The Journal of clinical endocrinology and metabolism, 85(8):2810\u20135.  \n\n13. Holterhus P. M., Werner R., Hoppe U., Bassler J., Korsch E., Ranke M. B., Hiort O. \n\n(2005). Molecular features and clinical phenotypes in androgen insensitivity syndrome in \n\nthe absence and presence of androgen receptor gene mutations. Journal of molecular \n\nmedicine, 83(12):1005\u201313.  \n\n14. Hughes, I. A. (2008). Disorders of sex development: a new definition and classification. \n\nBest practice &amp; research. Clinical endocrinology &amp; metabolism, 22(1):119\u201334.  \n\n15. Hughes I. A., Werner R., Bunch T., Hiort O. (2012). Androgen insensitivity syndrome. \n\nSeminars in Reproductive Medicine,  30(5):432-42.  \n\n16. J\u00e4\u00e4skel\u00e4inen J., Deeb A., Schwabe J. W., Mongan N. P., Martin H., Hughes I. A. (2006). \n\nHuman androgen receptor gene ligand-binding-domain mutations leading to disrupted \n\ninteraction between the N- and C-terminal domains, Journal of Molecular Endocrinology, \n\n36(2):361-8. \n\n17. K\u00f6hler B., Lumbroso S., Leger J., Audran F., Grau E. S., Kurtz F., Pinto G., Salerno M., \n\nSemitcheva T., Czernichow P., Sultan C. (2005). Androgen insensitivity syndrome: somatic \n\nmosaicism of the androgen receptor in seven families and consequences for sex assignment \n\nand genetic counseling. Journal Clinical Endocrinology and Metabolism, 90:106-111. \n\n18. Hiort O., Sinnecker G. H., Holterhus P. M., et al.(1996). The clinical and molecular \n\nspectrum of androgen insensitivity syndromes. American Journal of Medical Genetics, 63: \n\n218-222. \n\n19. Lubahn D. B., Joseph D. R., Sullivan P. M., Willard H. F., French F. S., Wilson E. M. \n\n(1988). Cloning of Human Androgen Receptor Complementary DNA and Localization to \n\nthe X Chromosome. Science, 240:327-330. \n\n20. McPhaul M. J., Marcelli M., Tilley W. D., Griffin J. E., Wilson J. D. (1991). Androgen \n\nresistance caused by mutations in the androgen receptor gene. FASEB Journal, 5:2910-\n\n2915. \n\n21. Mendonca B. B., Domenice S., Arnhold I. J. P., Costa E. M. F. (2009). 46,XY disorders of \n\nsex development (DSD). Clinical endocrinology, 70(2):173\u201387.  \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/23044881\n\n\n49 \n \n\n22. Melo K. F. S., Mendonca B. B., Billerbeck A. E. C., Costa E. M. F., In\u00e1cio M., Silva F. A. \n\nQ., Leal A. M. O., Latronico A. C., Arnhold I. J. P. (2003). Clinical, Hormonal, Behavioral \n\nand Genetic Characteristics of Androgen Insensitivity Syndrome in a Brazilian Cohort: \n\nFive Novel Mutations in the Androgen Receptor Gene. Journal of Clinical Endocrinology \n\n&amp; Metabolism, 88(7):3241\u20133250.  \n\n23. Moras D., Gronemeyer H. (1998). The nuclear receptor ligand-biding domain: structure and \n\nfunction. Current Opinion in Cell Biology, 10:384-391. \n\n24. Morris J. M. (1953). The syndrome of testicular feminization in male \n\npseudohermaphoditism. American Journal of Obstetrics and Gynecology, 65:1192-1211. \n\n25. Niaclean H. E., Warne G. L., Jeffrey D. (1997). General Review Localization of Functional \n\nDomains in the Androgen Receptor, Journal of Steroid Biochemistry and Molecular \n\nBiology, 62(4):233\u2013242. \n\n26. Petroli R. J., Maciel-Guerra A. T., Soardi F. C., de Calais F. L., Guerra-Junior G., de Mello \n\nM. P. (2011). Severe forms of partial androgen insensitivity syndrome due to p.L830F \n\nnovel mutation in androgen receptor gene in a Brazilian family. BMC research notes, \n\n4(1):173.  \n\n27. Powell S. M., Christiaens V., Voulgaraki D., Waxman J., Claessens F., Bevan C. L. (2004). \n\nMechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. \n\nEndocrine-related cancer, 11(1):117\u201330.  \n\n28. Quigley C. A., De Bellis A., Marschke K. B., E. L. Awady M. K., Wilson E. M., French F. \n\nS. (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. \n\nEndocrine, 16:271\u2013321. \n\n29. Tobo P. R., Barbosa A. S., Barbosa L. G., Sp\u00ednola-castro A. M., Moreira-filho C. A. \n\n(2003). Tr\u00eas muta\u00e7\u00f5es novas no gene receptor de andr\u00f3geno associado \u00e0 s\u00edndrome de \n\ninsensibilidade parcial do andr\u00f3geno: H570R, G589E e S759T Three novel mutations in the \n\nandrogen receptor gene associated with partial androgen, Einstein, 1:3. \n\n30. Van de Wijngaart D. J., Molier M., Lusher S. J., Hersmus R., Jenster G., Trapman J., \n\nDubbink H. J. (2010). Systematic structure-function analysis of androgen receptor Leu701 \n\nmutants explains the properties of the prostate cancer mutant L701H. The Journal of \n\nbiological chemistry, 285(7):5097\u2013105.  \n\n\n\n50 \n \n\n31. Werner R., Sch\u00fctt J., Hannema S., R\u00f6pke A., Wieacker P., Hiort O., Holterhus P. M. \n\n(2006). Androgen receptor gene mutations in androgen insensitivity syndrome cause \n\ndistinct patterns of reduced activation of androgen-responsive promoter constructs. The \n\nJournal of steroid biochemistry and molecular biology, 101(1):1\u201310.  \n\n32. Werner R., Zhan J., Gesing J., Struve D., Hiort O. (2008). In-vitro characterization of \n\nandrogen receptor mutations associated with complete androgen insensitivity syndrome \n\nreveals distinct functional deficits. Sexual development?: genetics, molecular biology, \n\nevolution, endocrinology, embryology, and pathology of sex determination and \n\ndifferentiation, 2(2):73\u201383.  \n\n33. Wong H. Y., Hoogerbrugge J. W., Pang K. L., Van Leeuwen M., Van Royen M. E., Molier \n\nM., Brinkmann A. O. (2008). A novel mutation F826L in the human androgen receptor in \n\npartial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain \n\ninteraction and TIF2 co-activation. Molecular and cellular endocrinology, 292(1-2):69\u201378.  \n\n34. Zhou J., Liu B., Geng G., Wu, J. H. (2010). Study of the impact of the T877A mutation on \n\nligand-induced helix-12 positioning of the androgen receptor resulted in design and \n\nsynthesis of novel antiandrogens. Proteins, 78(3):623\u201337.  \n\n35. Wang Q. I., Ghadessy F. J., Trounson A., Kretser D., McLachlan R., Yong E. L. (1998). \n\nAzoospermia associated with a mutation in the ligand-binding domain of an androgen \n\nreceptor displaying normal ligand binding, but defective trans-activation. Journal of \n\nClinical Endocrinology and Metabolism, 83: 4303-4309. \n\n36. Sack J. S., Kish K. F., Wang C., Attar R. M., Kiefer S. E., An Y., Wu G. Y., et al. (2001). \n\nCrystallographic structures of the ligand-binding domains of the androgen receptor and its \n\nT877A mutant complexed with the natural agonist dihydrotestosterone. Proceedings of the \n\nNational Academy of Sciences of the United States of America, 98(9):4904\u20139.  \n\n37. Grosdidier  S., Carb\u00f3 L. R., Buz\u00f3n V., Brooke G., Nguyen P., Baxter J. D., Bevan C., et al. \n\n(2012). Allosteric conversation in the androgen receptor ligand-binding domain surfaces. \n\nMolecular endocrinology, 26(7):1078\u201390.  \n\n38. Brown T. R., Scherer P. A., Chang Y. T., Migeon C. J., Ghirri P., Murono K., Zhou Z. \n\n(1993). Molecular genetics of human androgen insensitivity. European Journal of \n\nPediatrics, 152(2):S62-9. \n\n\n\n51 \n \n\n39. Yong E. L., Tut T. G., Ghadessy F. J., Prins G., Ratnam S. S. (1998). Partial androgen \n\ninsensitivity and correlations with the predicted three dimensional structure of the androgen \n\nreceptor ligand-binding domain. Molecular and cellular endocrinology, 137(1):41\u201350. \n\n40. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., Fischbeck K. H. (1991). \n\nAndrogen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature, \n\n4:352(6330):77-9. \n\n41. Werner R., Davies J., Brunch T., Struve D., Hiort O., Hughes I. A. (2009). N/C interaction \n\nof androgen mutation R840H is ligand and cell type dependent. Hormone Research. 72 \n\n(S3):PO3-088. \n\n42. Szafran A. T., Hartig S., Sun H., Uray I. P., Szwarc M., Shen Y., Mediwala S. N., et al. \n\n(2009). Androgen receptor mutations associated with androgen insensitivity syndrome: a \n\nhigh content analysis approach leading to personalized medicine. PloS one, 4(12):e8179.  \n\n43. Buz\u00f3n V., Carb\u00f3 L. R., Estruch S. B., Fletterick R. J., Est\u00e9banez-Perpi\u00f1\u00e1, E. (2012). A \n\nconserved surface on the ligand binding domain of nuclear receptors for allosteric control. \n\nMolecular and cellular endocrinology, 348(2):394\u2013402.  \n\n44.  De Leon J. T., Iwai A., Feau C., Garcia Y., Balsiger H., Storer C. L., Suro R. M., et al. \n\n(2011). Targeting the regulation of androgen receptor signaling by the heat shock protein \n\n90 cochaperone FKBP52 in prostate cancer cells. Proceedings of the National Academy of \n\nSciences of the United States of America, 108(29):11878\u201383.  \n\n45.  Lanz R. B., Rusconi S. (1994). A conserved carboxy-ter- minal subdomain is important for \n\nligand in- terpretation and transactivation by nuclear receptors. Endocrinology 135: 2183\u2013\n\n2195. \n\n46. Tahiri B., Auzou G., Nicolas J. C., Sultan C., Lupo B. (2001). Participation of critical \n\nresidues from the ex- treme C-terminal end of the human andro- gen receptor in the ligand \n\nbinding function. Biochemistry, 40: 8431\u20138437  \n\n47. Takahashi H., Furusato M., Allsbrook W. C., Nishii H., Wakui S., Barrett J. C. et al. \n\n(1995). Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from \n\nJaponese men. Cancer Research, 55:1621-4. \n\n \n\n \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=La%20Spada%20AR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=2062380\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Wilson%20EM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=2062380\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Lubahn%20DB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=2062380\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Harding%20AE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=2062380\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Fischbeck%20KH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=2062380\n\n\n52 \n \n\n5. Cap\u00edtulo 3 \n\n \n\nArtigo 3: \n\n \n\nFunctional studies for p.Pro695Ser androgen \n\nreceptor mutation: association with gynecomastia \n\nand fertility \n\n \n\nReginaldo J Petroli, M.S.,\na,b\n\n Olaf Hiort, M.D., Ph.D.,\nb\n Dagmar Struve, B.S.,\n\nb\n Andr\u00e9a Trevas \n\nMaciel-Guerra, M.D., Ph.D.,\nc\n Gil Guerra-Junior, M.D., Ph.D.,\n\nd\n Maricilda Palandi de Mello, \n\nPh.D.,\na\n and Ralf Werner, Ph.D.\n\nb\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n53 \n \n\n\u2022 Running title. Male Fertility associated with AR mutation \n\n\u2022 Title. Functional studies for p.Pro695Ser androgen receptor mutation: association with \n\ngynecomastia and fertility \n\n \n\n\u2022 Author names and affiliations.  \n\nReginaldo J Petroli, M.S.,\na,b\n\n Olaf Hiort, M.D., Ph.D.,\nb\n Dagmar Struve, B.S.,\n\nb\n Andr\u00e9a Trevas \n\nMaciel-Guerra, M.D., Ph.D.,\nc\n Gil Guerra-Junior, M.D., Ph.D.,\n\nd\n Maricilda Palandi de Mello, \n\nPh.D.,\na\n and Ralf Werner, Ph.D.\n\nb\n \n\n \n\na\n Centro de Biologia Molecular e Engenharia Gen\u00e9tica, Universidade Estadual de \n\nCampinas, Campinas, S\u00e3o Paulo, Brasil; \nb\n Department of Paediatrics and Adolescent \n\nMedicine, Division of Paediatric Endocrinology and Diabetes, University of Luebeck, \n\nLuebeck, Germany; \nc \n\nDepartamento de Gen\u00e9tica M\u00e9dica; \nd \n\nDepartamento de Pediatria, \n\nUniversidade Estadual de Campinas, Campinas, S\u00e3o Paulo, Brasil. \n\n \n\nCapsule \n\n \n\nGynecomastia and fertility in androgen insensitivity syndrome correlate to p.Pro695Ser \n\nmutation in the androgen receptor gene. The expression profile suggests a high dose DHT \n\ntherapy to overcome functional deficits. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n54 \n \n\nStructured Abstract \n\n \n\nObjective: To search for mutation in the androgen receptor gene and to evaluate its \n\ninfluence on the androgen receptor transactivation ability.  \n\nDesign: Androgen receptor gene sequencing and in vitro assays for androgen receptor \n\ntransactivation activity comparing normal and mutant proteins. \n\n Setting: University research. \n\nPatient(s): A fertile man with gynecomastia. \n\nIntervention(s): Peripheral whole blood.  \n\nMain Outcome Measure(s): A mutation in the androgen receptor gene presenting \n\ntransactivation activities that correlate to mild form of androgen insensitivity syndrome. \n\nResult(s): Androgen receptor gene sequencing revealed the p.Pro695Ser mutation. It is \n\nlocated within the androgen receptor ligand-binding domain. Bioinformatics analysis \n\nindicated a deleterious role, which was verified upon testing transctivation activity and N/C \n\ninteraction by in vitro expression of a reporter gene and two hybrid assays. p.Pro695Ser \n\nshowed low levels of both transactivation activity and N/C interaction at low \n\ndihydrotestosterone conditions. As the ligand concentration increases both transactivation \n\nactivity and N/C interaction also increase and reach normal levels. \n\nConclusion(s): This study provides functional insights for the p.Pro695Ser mutation \n\ndescribed here for the first time in a patient with mild androgen insensitivity syndrome. The \n\nexpression profile p.Pro695Ser not only correlates to the patient\u2019s phenotype but also \n\nsuggests that a high dose DHT therapy may overcome the functional deficit of the androgen \n\nreceptor. \n\nKey Words: androgen receptor gene, gynecomastia, male fertility, p.Pro695Ser mutation.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n55 \n \n\nIntroduction \n\n \n\nThe androgen insensitivity syndrome (AIS) is known as a disorder caused by \n\nmutations in the androgen receptor gene (AR) but in the absence of AR mutations it can \n\nresult from abnormalities in some unknown mechanism (1-3). Individuals 46,XY with AIS \n\npresent undermasculinization with external genitalia that varies from normal male to \n\nfemale. Based on the degree of masculinization the disorder is divided in three main \n\nsubgroups: mild AIS (MAIS) characterized by infertility or gynecomastia; partial AIS \n\n(PAIS) that is associated with different degrees of masculinization of external genitalia, that \n\nmanifests as micropenis, severe hypospadia, bifid scrotum or clitoris enlargement with \n\nlabial fusion; and, complete AIS (CAIS) that results in a female phenotype with sparse to \n\nabsent pubic and axillary hair and normal breast development (1, 3, 4-6). \n\nThe AR gene maps to the X-chromosome at Xq11 \u2013 12 region. Mutations on this \n\ngene can be either inherited with a X-chromosomal recessive inheritance or sporadic. The \n\nAR gene has eight exons and seven introns distributed on more than 186 kb (7-9).  \n\nThe AR gene codes for a protein with approximately 920 amino acids and molecular \n\nweight of about 110 kD. The AR protein exhibits three functional domains: the variable \n\namino-terminal domain (NTD) that extends from residue 1 to 538, and is involved in the \n\nAR transactivation activity through interaction with the transcriptional machinery (10); the \n\nconserved DNA-binding domain (DBD) formed by residues 539 to 628 (11, 12); and, the \n\nconserved ligand-binding domain (LBD) from residue 670 to 920. The LBD contains 11 \n\nhelices that are responsible for the organization of ligand-binding pocket which is formed \n\nby helices 3, 4, 5, 7, 11 and 12 and also the beta-sheet preceding helix 6 (13). The LBD also \n\nharbors an important and conserved region, the ligand-dependent activation function 2 (AF-\n\n2) (14, 15). Interaction between N-terminal domain and C-terminal domain of AR protein is \n\nan important step toward the activation of AR. Any damage in the N/C interaction can be \n\nassociated with AIS, even if the hormone binding is normal (17-20). \n\nMutations in the AR may result in decrease of ligand affinity, cause a disturbance in \n\nco-activator interactions or also cause damages in the DNA-binding activity depending on \n\nwhich residue is involved (15, 21). There are more than 800 different AR mutations (22) \n\nreported in the literature that are associated to phenotypes that range from MAIS to CAIS.  \n\n\n\n56 \n \n\nIn general, mutations associated to MAIS cause male infertility. Here, we describe a \n\nrare case of a fertile patient with MAIS due to the p.Pro695Ser AR mutation. To understand \n\nthe functional properties of this mutation, we studied its impact mutation on both full length \n\nAR transactivation ability and AR N/C-terminal interaction. \n\nPatient and Methods \n\nPatient  \n\nThe patient, a 27-year-old man, was referred to us due to persistent gynecomastia. \n\nBreast development began spontaneously at the age of 11.5 years and progressed during a \n\nperiod of 4 years; afterwards, the gynecomastia stabilized. There was no history of use of \n\ndrugs such as androgenic or estrogenic hormones and antiandrogens that could have a \n\ncausative association with gynecomastia. His parents were not consanguineous, and there \n\nwas no family history of gynecomastia, genital ambiguity or infertility. On physical \n\nexamination, his weight was 87.6 kg, height 169.5 cm and arm span 170 cm; breast \n\ndevelopment was equivalent to Tanner stage III, and both glandular and fat tissues were \n\npalpable. He had male external genitalia with a small phallus (7.7 cm stretched length) and \n\ntestes were located in the scrotum (right testis = 25 cm\n3\n, left testis = 20 cm\n\n3\n). Facial and \n\naxillary hair was sparse. He had a normal 46,XY karyotype. Levels of FSH (2.03 IU/L; \n\nnormal range (NR)=1.5-12.4) and estradiol (36.04 pg/mL; NR=7.6-42.6 pg/mL) were \n\nwithin the normal male reference range; whereas LH (8.77 IU/L; NR=1.7-8.6) and \n\ntestosterone (30.99 nmol/L; NR=9.92-28.11 nmol/L) levels were slightly elevated. The \n\nAndrogen Sensitivity Index (LH x Testosterone in U x nmol/L\n2\n) was elevated (271 U x \n\nnmol/L\n2\n;\n \nNR=&lt;138 U x nmol/L\n\n2\n) suggesting AIS (23). He had two sperm analyses that \n\nshowed concentrations within the normal range (29 and 25 millions/mL; normal = >20 \n\nmillions/mL) and indicated normal sperm morphology and motility. Each of two ex-wives \n\nhad miscarriages, and his current wife gave birth to a healthy boy. This study had been \n\napproved by the Institutional Review Board at Universidade Estadual de Campinas (# \n\n434/2006). \n\nMolecular Analysis of AR Gene \n\nGenomic DNA was isolated from whole blood samples with standard procedures \n\nusing Proteinase K lysis and phenol/chloroform extraction. The eight AR exons and exon-\n\nintron junctions had been amplified by PCR using primers and PCR conditions described \n\n\n\n57 \n \n\nelsewhere (6). PCR products were purified using the Wizard\u00ae SV Gel and PCR clean-up \n\nsystem (Promega, Madison, WI, USA). Further direct sequencing using ABI PRISM Big \n\nDye Terminator v3.1 Cycle Sequencing Kit (ABI PRISM/PE Biosystems, Foster City, CA, \n\nUSA) was carried out using sense and antisense primers. Sequences were obtained in an \n\nABI PRISM 3130 DNA Analyzer (ABI PRISM/PE Biosystems). Free softwares such as \n\nChromas Pro v.1.5 and CLC Sequence Viewer v.6.6.2 were used to analyze and compare \n\nsequences with the AR reference sequence at Ensembl database (ENSG00000169083, 24). \n\nPreparation of AR expression vectors \n\nThe mutation was introduced into the full-length AR expression vector pSVAR0, \n\nwhich was kindly provided by Dr. A. Brinkmann from the University Hospital Rotterdam, \n\nRotterdam, NL. PCR based site-directed mutagenesis was carried out in two steps using the \n\nfollowing primers: AR_Pro695Ser_sense: 5\u2019-\n\nCACGACAACAACCAGTCCGACTCCTTTGCAG-3\u2019; AR_Pro695Ser_antissense: 5\u2019-\n\nCTGCAAAGGAGTCGGACTGGTTGTTGTCGTG-3\u2019. In the first step, primer \n\nAR_LBD644s (5\u00b4-GAGGCTTCCAGCACCACCA-3\u00b4) and the respective mutagenesis \n\nantisense primer were used. The second amplification was performed with the respective \n\nmutagenesis sense primer and pSV0seq_as (5\u2019- TGATAGGCAGCCTGCACCTGA -3\u2019). \n\nBoth amplicons were gel purified, combined, annealed and amplified in a third PCR using \n\nthe primer pair AR_LBD644s - pSV0seq_as. Mutant amplicons were double digested with \n\nTth111I/PstI and subcloned into pSVAR0. The insert and its cloning borders were verified \n\nby sequencing.  \n\nTwo Hybrid Constructs \n\nAR N/C interaction was analyzed using the mammalian two-hybrid assay kit \n\n(Stratagene, La Jolla, CA). In order to generate mammalian two-hybrid clones containing \n\nthe GAL4 DNA binding domain fused to AR618-920, the AR LBD618-920 was amplified using \n\nspecific primers, previously described in Werner et al. (19).   \n\nLuciferase Gene Assays  \n\nThe p(ARE)2TATA-Luc vector, which contains two androgen response elements 5\u2019 \n\nof the TATA-box preceding the firefly luciferase gene, was a kind gift of Dr. G. Jenster \n\nfrom Josephine Nefkens Institute, Erasmus MC (Rotterdam, NL). The pFR-Luc vector \n\n(Stratagene, La Jolla, CA) contains a synthetic promoter with five tandem repeats of yeast \n\n\n\n58 \n \n\nGAL4 binding sites which control expression of the firefly luciferase gene and served as a \n\nreporter gene in mammalian two hybrid assays. Plasmid phRGTK contains a constitutive \n\nactive Renilla luciferase reporter gene used to normalize transfection efficiency in Dual \n\nLuciferase Assays (Promega). \n\nTransient transfections of full length AR and two hybrid assays \n\nThe Chinese hamster ovary (CHO) cells were used to express the wild type and \n\nmutant AR proteins. Transfection experiments were performed as previously described \n\n(25). 80.000 cells/well were cultured overnight in 24 well plates with Dulbecco\u2019s modified \n\nEagles Medium/Nutrient Mixture F-12 Ham (DMEM/F12, Sigma-Aldrich Co., St. Louis, \n\nMO) supplemented with 10% dextran charcoal-stripped fetal calf serum in 5% CO2 at \n\n37\u00b0C. Then 30 ng wt-AR or mutant plasmid DNA were co-transfected with 200 ng \n\np(ARE)2TATA-Luc and 5 ng phRGTK using 0.5 \u00b5l FuGENE HD (Promega Corp., \n\nMadison, WI).  \n\nFor N/C interaction assays CHO cells were cultured and seeded in 24 well plates as \n\ndescribed above. 100 ng pBD-LBD618-920 (bait, wild type or mutant) and 100 ng of pAD-\n\nNTD1-536 (prey) were co-transfected with 200 ng pFR-Luc (reporter gene) and 10 ng \n\nphRGTK per well using 1.0 ?l FuGENE HD (Promega). For both experiments, five hours \n\nafter transfection, 0\u2013100 nmol/l DHT were added to each well. The luciferase activity was \n\ndetermined 18 h after hormone induction, using a Dual Luciferase assay (Promega) and \n\nnormalized to transfection efficiency. For comparison of experiments performed at \n\ndifferent days we set the transactivity of wt-AR at 10 nmol/l DHT as 100%. Relative \n\nluciferase units (RLU) of other samples assayed at the same time were expressed relative to \n\nthis value. For statistical analysis, all transfections were performed in triplicate and at least \n\nthree independent experiments were performed. \n\nWestern blot analysis \n\nFor protein expression analysis of AR full length constructs 300.000 CHO cells \n\nwere grown in six well culture plates overnight. Cells were transfected using 1 ?g (ARE)2 \n\nTATA-Luc plasmid, 150 ng wild type or mutant AR plasmid, 25 ng phRGTK and 3.35 ?l \n\nFugene HD reagent per well. For analysis of two-hybrid constructs 80.000 CHO cells were \n\ngrown in twenty four well culture plates overnight and were transfected as described above. \n\nAfter 18 h, cells were washed twice with cold PBS and lysed in 250 ?l M-PER lysis buffer \n\n\n\n59 \n \n\n(Pierce, Rockford, IL) including complete proteinase inhibitor (Roche, Mannheim, \n\nGermany) on ice for 5 min. Cells were scraped and collected for Western blot analysis. \n\nProtein concentration was estimated by Bio-Rad protein assay (Bio-Rad, Richmont, CA). \n\nThe remainder of protein was dissolved in SDS sample buffer and denatured by heating at \n\n95\u00b0C for 10 minutes followed by SDS-PAGE.  \n\nFull-length AR was detected with primary antibody anti AR F39.4.1 (Innogenex, \n\nSan Ramon, CA) diluted 1:500. GAL4-LBD fusion proteins were detected with primary \n\nantibody AR-C19 (sc-815, Santa Cruz Biotechnology Inc.) diluted 1:200. Signals were \n\nvisualized using the corresponding conjugated anti-mouse or anti-rabbit secondary antibody \n\napplying the Western Lightning Chemiluminescent Reagent Plus (PerkinElmer, Boston, \n\nMA) and a Fusion SL chemiluminescent imager (Vilbert Lourmat). \n\nResults \n\nAR gene sequencing identified the c.2083C>T nucleotide change within exon 4. \n\nThis change leads to p.Pro695Ser mutation in the LBD region. \n\nTo investigate the effect of the AR p.Pro695Ser mutant protein on AR \n\ntransactivation capability, the full-length AR plasmids were co-transfected with the firefly \n\nluciferase reporter plasmid p(ARE)2TATA-Luc in CHO cells (Fig. 1A). Expression of \n\ncomparable amounts of wild-type (wt) and mutant proteins was confirmed by Western \n\nblotting (Fig. 2A).  \n\nAt low DHT concentrations (0.1-0.33 nM) the AR p.Pro695Ser mutation showed a \n\nreduced transactivation of the reporter gene reaching approximately 60% of the wild type \n\nlevel (Fig. 1A). Physiological DHT concentrations of 1.0-3.3 nM still showed a small but \n\nsignificant reduced transactivation (t-test: P<0.001), while high and supraphysiological \n\nDHT concentrations (10-100 nM) rescued full AR transactivation activity.  \n\nThe effect of AR p.Pro695Ser on N/C terminal interaction was tested using \n\nmammalian two hybrid assays (Fig. 1B). Similar results were obtained, where DHT \n\nconcentrations of 1 nM still lead to a significantly reduced transactivation of the reporter \n\ngene (t-test, P<0.001), indicating a reduced binding of the FxxLF motif to AF-2. On the \n\nother hand, higher DHT concentrations (3.3-100 nM) fully restored N/C-interaction (Fig. \n\n1B). Expression of comparable amounts of wild-type (wt) and mutant Gal4-LBD fusion \n\nproteins was confirmed by Western blotting (Fig. 2B). \n\n\n\n60 \n \n\nDiscussion \n\nThe clinical manifestation of p.Pro695Ser mutation in the patient described here was \n\ngynecomastia with elevated LH and testosterone serum levels. These levels contributed to a \n\nhigh androgen sensitivity index suggesting MAIS. Besides clinical features of the patient \n\nand the molecular findings, we describe in this study the functional activity of \n\np.Pro695Ser mutation that is located in the LBD of AR protein.  \n\nThe alignment of human AR protein sequence to other mammalian AR proteins \n\nindicated that P695 residue is conserved among all mammalian species (data not shown). \n\nMutations located in this residue are expected to drastically damage the receptor structure \n\nand function as mutations surround it were mainly found in 46,XY female patients with \n\nnormal or ambiguous genitalia (22, 26-28).  \n\nThe c.2083C>T nucleotide change responsible for p.Pro695Ser mutation have not \n\nbeen annotated yet in the Androgen Receptor Gene Mutations Database (22), whereas it \n\nwas reported as a single nucleotide variation (SNV) in the NHLBI GO Exome Sequencing \n\nProject (ESP) with the reference # rs372903533 (29). As the individual carrying the \n\nmutation was a heterozygous female, no clinical significance has been associated to it. \n\nConversely, SIFT and PolyPhen predictive algorithms theoretically considered the \n\np.Pro695Ser as a deleterious mutation.  \n\nThe functional significance of the mutant p.Pro695Ser AR protein was tested in \n\nvitro and the results indicated impairments in both transcriptional activity and in N/C \n\ninteraction under low hormone concentration conditions. Both functionalities are gradually \n\nrecovered as DHT concentration increases. Although they still remained significantly lower \n\nat physiological hormone concentrations, they were very close to the wild-type; whereas, at \n\nhigh DHT concentrations they were fully recovered. \n\nThe mild impairment of AR transactivation capacity observed in vitro for \n\np.Pro695Ser mutant under physiological conditions associated it to MAIS phenotype. N/C-\n\nterminal interaction is critical for AR transactivation and is predominantly mediated by \n\nbinding of the N-terminal FxxLF motif (residues 23-27) to the hydrophobic binding groove \n\nof AF-2 in LDB (30). According to the crystallographic structure of the ligand-binding \n\ndomain of the androgen receptor, the residue P695 is located in the loop between helix 1 \n\nand helix 3 of AR protein (13). Based on results for the p.Asp696Asn mutation, this region \n\n\n\n61 \n \n\nwas considered to be important for N/C interaction  (15). This mutation did not affect \n\nligand-binding but drastically reduced transactivation activity through impairment of N/C \n\ninteraction. Therefore, we tested N/C interaction for p.Pro695Ser to verify the possible \n\ninfluence upon transactivation activity. A significant reduction in the N/C interaction was \n\nonly observed at low DHT concentrations (? 1.0 nM) confirming the mild effect of the \n\nmutation. \n\nIn general, fertility in MAIS patients is a very rare feature. Larrea et al. (31) \n\ndescribed four individuals in a family with gynecomastia and normal fertility due to MAIS, \n\nbut molecular evaluation was not available at that time. Besides p.Pro695Ser here \n\ndiscussed, two other mutations, p.Arg825Lys and p.Arg841Cys, have been associated to \n\nMAIS without affecting fertility (32, 33). Similarly to the mutation described here, those \n\nmutations present an increase in AR activity as DHT concentration increases. In the family \n\ndescribed by Chu et al. (33) the p.Arg841Cys mutation was associated with fertile and \n\ninfertile 46,XY individuals. Based on the improvement in the AR activity in higher \n\nandrogen concentrations, the authors discuss that the variation in phenotype among the \n\ndifferent patients may be explained by fluctuation in androgen secretion during certain \n\nperiods of sexual development. Among morphological features in fertile individuals with \n\nMAIS described by Chu et al. (33) and Giwercman et al. (32) hypospadias, gynecomastia \n\nand diminished penis size can be found. Gynecomastia was the only morphological feature \n\nin the patient we describe. As this condition is a result of excessive estrogen actions due to \n\nan increased ratio of estrogen to androgen associated with low activity of androgen \n\nreceptor, it is reasonable to think that the level of testosterone in the breast was not enough \n\nto rescue the activity of the mutated androgen receptor in the patient; whereas, a higher \n\ntestosterone concentration in the testis might have preserved fertility as the mutant receptor \n\nrecovers its transactivation activity under ligand high level conditions. \n\nIn conclusion, we describe for the first time the association of p.Pro695Ser with a \n\nmild form of androgen insensitivity in a fertile individual whose complain was \n\ngynecomastia. In vitro analysis confirmed the role of the mutation on MAIS ethiology and \n\ngave clues for choosing an appropriate therapy for the patient as well. The results suggest \n\nthat a high dose DHT therapy may overcome the functional deficit of the receptor. \n\nAlthough many studies on the AR protein have already been described in the literature, \n\n\n\n62 \n \n\nnovel mutations and their effects can give insights for understanding how they are reflected \n\nin the phenotype of each patient. \n\n \n\nAcknowledgements \n\nAuthors would like to thank Mr. Wanderley Pedroso da Gra\u00e7a from Laborat\u00f3rio Nacional \n\nde Bioci\u00eancias, CNPEM/ABTLuS sequencing facility and also Mrs. Alessandra Oliveira \n\nfrom Laborat\u00f3rio Multiusu\u00e1rio, CBMEG, UNICAMP. \n\nThe authors address a special thanks to Mrs. Cristiane dos Santos Cruz Piveta \n\nfor technical support. This work was supported by grants #  2009/08320-9 (MPM) and \n\nscholarships # 2008/01964-5 (RJP) from Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o \n\nPaulo (FAPESP). This work was also supported by grants from Coordena\u00e7\u00e3o de \n\nAperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) to RJP and Conselho \n\nNacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq - Brasil) to \n\nGGJ and MPM. \n\n\n\n63 \n \n\nReferences \n\n1. Quigley CA, De Bellis A, Marschke KB, EL-Awady MK, Wilson EM, French FS. \n\nAndrogen receptor defects: historical., clinical., and molecular perspectives. Endocr Rev \n\n1995;16:271\u2013321. doi: 10.1210/edrv-16-3-271. \n\n2. Hughes IA. Disorders of sex development: a new definition and classification. Best Pract \n\nRes Clin Endocrinol Metab 2008;22:119\u201334. doi: 10.1016/j.beem.2007.11.001. \n\n3. Brinkmann, AO. Molecular mechanisms of androgen action.  In: Saatcioglu F, eds. \n\nAndrogen Action: Methods in Molecular Biology, New York: Humana Press, 2011; 776: 3-\n\n24. doi: 10.1007/978-1-61779-243-4_1. \n\n4. Morris, J.M. The syndrome of testicular feminization in male pseudohermaphoditism. Am J \n\nObstet Gynecol 1953;65:1192-211.  \n\n5. Hughes IA, Werner R, Bunch T, Hiort O. Androgen insensitivity syndrome. Semin Reprod \n\nMed 2012;30:432-42. doi: 10.1055/s-0032-1324728. \n\n6. Petroli RJ, Maciel-Guerra AT, Soardi FC, de Calais FL, Guerra-Junior G, de Mello MP. \n\nSevere forms of partial androgen insensitivity syndrome due to p.L830F novel mutation in \n\nandrogen receptor gene in a Brazilian family. BMC Res Notes 2011; 4:173. doi: \n\n10.1186/1756-0500-4-173. \n\n7. Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino \n\nacid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A \n\n1988;85:7211\u20135.  \n\n8. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of \n\nHuman Androgen Receptor Complementary DNA and Localization to the X Chromosome. \n\nScience 1988;240:327-30. \n\n9. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, et al. \n\nCloning, structure and expression of a cDNA encoding the human androgen receptor. \n\nBiochem Biophys Res Commun1988;153:241-8. \n\n10. MacLean HE, Warne GL, Jeffrey D. Localization of Functional Domains in the Androgen \n\nReceptor. J Steroid Biochem Mol Biol 1997;62:233\u201342. doi: 10.1016/S0960-\n\n0760(97)00049-6. \n\n11. Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. The hinge region in androgen \n\nreceptor control. Mol Cell Endocrinol 2012; 358: 1\u20138. doi: 10.1016/j.mce.2012.02.019. \n\n\n\n64 \n \n\n12. Helsen C, Kerkhofs S, Clinckemalie L, Spans L, Laurent M, Boonen S, et al. Structural \n\nbasis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 2012;348:411\u20137. \n\ndoi: 10.1016/j.mce.2011.07.025. \n\n13. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, et al. Crystallographic structures \n\nof the ligand-binding domains of the androgen receptor and its T877A mutant complexed \n\nwith the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001; 98:4904\u20139. \n\ndoi: 10.1073/pnas.081565498. \n\n14. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol \n\n2001;179:105-9. Doi: 10.1016/S0303-7207(01)00466-X. \n\n15. J\u00e4\u00e4skel\u00e4inen J, Deeb A, Schwabe JW, Mongan NP, Martin H, Hughes IA. Human androgen \n\nreceptor gene ligand-binding-domain mutations leading to disrupted interaction between \n\nthe N- and C-terminal domains. J Mol Endocrinol 2006;36:361-8.doi:10.1677/jme.1.01885. \n\n16. Powell, S. M., Christiaens, V., Voulgaraki, D., Waxman, J., Claessens, F., &amp; Bevan, C. L. \n\nMechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. \n\nEndocr Relat Cancer 2004;11:117\u201330. 1351-0088/04/011\u2013117. \n\n17. He B, Gampe RT, Hnat AT, Faggart JL, Minges JT, French FS, et al. Probing the \n\nfunctional link between androgen receptor coactivator and ligand-binding sites in prostate \n\ncancer and androgen insensitivity. J Biol Chem 2006;281:6648\u201363. \n\ndoi:10.1074/jbc.M511738200. \n\n18. Est\u00e9banez-Perpi\u00f1\u00e1 E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, et al. A \n\nsurface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl \n\nAcad Sci U S A 2007; 104:16074\u20139. doi: 10.1073/pnas.0708036104. \n\n19. Werner R, Zhan J, Gesing J, Struve D, Hiort O. In-vitro characterization of androgen \n\nreceptor mutations associated with complete androgen insensitivity syndrome reveals \n\ndistinct functional deficits. Sex Dev 2008; 2:73\u201383. doi:10.1159/000129692. \n\n20. Zhou J, Liu B, Geng G, Wu JH. Study of the impact of the T877A mutation on ligand-\n\ninduced helix-12 positioning of the androgen receptor resulted in design and synthesis of \n\nnovel antiandrogens. Proteins 2010;78:623\u201337. doi: 10.1002/prot.22592. \n\n21. Hughes IA, Deeb A. Androgen resistance. Best Pract Res Clin Endocrinol Metab \n\n2006;20:577\u201398. doi:10.1016/j.beem.2006.11.003.  \n\n\n\n65 \n \n\n22. The Androgen Receptor Gene Mutations Database available at http://androgendb.mcgill.ca. \n\nAccessed Mach 14, 2014. \n\n23. Hiort O, Holterhus PM, Horter T, Schulze W, Kremke B, Bals-Pratsch M, et al. \n\nSignificance of mutations in the androgen receptor gene in males with idiopathic infertility. \n\nJ Clin Endocrinol Metab 2000;85:2810\u20135. doi:10.1210/jcem.85.8.6713. \n\n24. The Ensembl project  available at http://www.ensembl.org. Accessed Mach 14, 2014. \n\n25. Werner R, Sch\u00fctt J, Hannema S, R\u00f6pke A, Wieacker P, Hiort O, et al. Androgen receptor \n\ngene mutations in androgen insensitivity syndrome cause distinct patterns of reduced \n\nactivation of androgen-responsive promoter constructs. J Steroid Biochem Mol Biol \n\n2006;101:1\u201310. doi: 10.1016/j.jsbmb.2006.06.016. \n\n26. Cheikhelard A, Morel Y, Thibaud E, Lortat-Jacob S, Jaubert F, Polak M et al. Long-term \n\nfollow-up and comparison between genotype and phenotype in 29 cases of complete \n\nandrogen insensitivity syndrome. J Urol 2008;180:1496\u2013501. doi: \n\n10.1016/j.juro.2008.06.045. \n\n27. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. Inherited and de novo \n\nandrogen receptor gene mutations: investigation of single-case families. Journal of \n\npediatrics1998, 132(6), 939\u201343. doi:10.1016/S0022-3476(98)70387-7. \n\n28. D\u00f6rk T, Schnieders F, Jakubiczka S, Wieacker P, Schroeder-Kurth T, Schmidtke J. A new \n\nmissense substitution at a mutational hot spot of the androgen receptor in siblings with \n\ncomplete androgen insensitivity syndrome. Hum Mutat 1998;11:337-9.  \n\n29. NHLBI Exome Sequencing Project (ESP) available at \n\nhttp://evs.gs.washington.edu/EVS/ServletManager?variantType=snp&amp;popID=EuropeanAm\n\nerican&amp;popID=AfricanAmerican&amp;SNPSummary.x=58&amp;SNPSummary.y=12. Accessed \n\nMach 14, 2014. \n\n30. He B, Wilson EM. The NH(2)-terminal and carboxyl-terminal interaction in the human \n\nandrogen receptor. Mol Genet Metab 2002;75:293\u20138. doi: 10.1016/S1096-7192(02)00009-\n\n4. \n\n31. Larrea F, Benavides G, Scaglia H, Kofman-Alfaro S, Ferrusca E, Medina M, et al. \n\nGynecomastia as a familial incomplete male pseudohermaphroditism type 1: a limited \n\nandrogen resistance syndrome. J Clin Endocrinol Metab 1978;46:961\u201370.  doi: \n\n10.1210/jcem-46-6-961. \n\n\n\n66 \n \n\n32. Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, et al. Preserved \n\nMale Fertility Despite Decreased Androgen Sensitivity Caused by a Mutation in the \n\nLigand-Binding Domain of the Androgen Receptor Gene. J Clin Endocrinol Metab \n\n2000;85: 2253-59. doi: 10.1210/jcem.85.6.6626. \n\n33.  Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, et al. Male fertility is compatible with an \n\nArg(840)Cys substitution in the AR in a large Chinese family affected with divergent \n\nphenotypes of AR insensitivity syndrome. J Clin Endocrinol Metab 2002; 87:347\u201351. \n\ndoi:10.1210/jcem.87.1.8167. \n\n \n\n \n\n Figures: \n\n \n\nFigure 1.  Transactivation and N/C interaction for wt and mutant AR. A) Transactivation \n\nassay: CHO cells were transfected with the androgen-responsive firefly-luciferase reporter \n\ngene p(ARE)2 TATA-Luc, the Renilla luciferase plasmid phRGTK and full-length wt AR \n\nor AR_ p.Pro695Ser. Five hours after transfections, cells were treated with indicated \n\nconcentrations of DHT. B) N/C-Interaction assay: CHO cells were transfected with \n\npAD_NTD fusion construct, pFR_Luc, phRGTK (Renilla luciferase) and pBD_LBD_wt or \n\npBD_LBD_p.Pro695Ser. Five hours after transfections, cells were treated with indicated \n\nconcentrations of DHT. In both experiments, transfection efficiencies were normalized \n\nusing the Dual Luciferase Assay kit. The activity of the wt constructs at 10 nM DHT was \n\nset to 100%. At least three independent experiments were performed in triplicates, error \n\nbars + 1 SD. RLU: relative luciferase units. \n\n \n\n\n\n67 \n \n\n \n\n \n\n \n\nFigure 2. Western blot analysis of wt and mutant AR. (A) mutant p.Pro695Ser (lane 1), wt \n\nfull length AR (lane 2) and non-transfected CHO cells (lane 3) incubated with anti-AR \n\nantibody F39.4.1. (B) GAL4-DBD/AR-LBD fusion constructs detected with AR-C19 \n\nantibody; lane 1: non-transfected CHO cells, lanes 2-5: wt AR fusion protein incubated \n\nwith 0 nM, 0.1 nM, 1 nM, and 10 nM DHT and lanes 6-9: p.Pro695Ser fusion protein \n\nincubated with 0 nM, 0.1 nM, 1 nM and 10 nM DHT. Detection of ?-actin was performed \n\non the same membrane as a loading control for the experiment.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n68 \n \n\n6. Discuss\u00e3o: \n\n \n\nAtrav\u00e9s do sequenciamento autom\u00e1tico do gene AR, pode-se observar as muta\u00e7\u00f5es \n\ndescritas nos artigos 1 a 3 e a partir delas, as an\u00e1lises funcionais foram realizadas. No artigo \n\n1 descrevemos uma fam\u00edlia com quadro cl\u00ednico sugestivo de AIS, o que foi confirmado \n\ncom a an\u00e1lise por sequenciamento, onde foi observada a troca nucleot\u00eddica c.3015C>T no \n\nexon 7 do gene AR, levando \u00e0 muta\u00e7\u00e3o p.Leu830Phe, associada ao fen\u00f3tipo PAIS. Esta \n\naltera\u00e7\u00e3o, descrita pela primeira vez neste trabalho, foi avaliada quanto \u00e0 conserva\u00e7\u00e3o do \n\nres\u00edduo e a suas altera\u00e7\u00f5es estruturais. As an\u00e1lises indicaram que o res\u00edduo \u00e9 bastante \n\nconservado e que mudan\u00e7as no microambiente onde se deu a muta\u00e7\u00e3o ocorreram, sendo \n\npossivelmente relacionadas com o comprometimento funcional do AR. \n\nO artigo 2 mostra a an\u00e1lise funcional de seis muta\u00e7\u00f5es e uma combina\u00e7\u00e3o entre \n\nduas muta\u00e7\u00f5es associadas aos fen\u00f3tipos PAIS e CAIS, incluindo a p.Leu830Phe descrita no \n\nartigo 1. As altera\u00e7\u00f5es relacionadas ao fen\u00f3tipo PAIS: p.Ser759Tre, p.Leu830Phe e \n\np.Ile898Phe apresentaram resultados semelhantes em concentra\u00e7\u00f5es sub-fisiol\u00f3gicas (0,1-\n\n0,33 nM DHT) e fisiol\u00f3gica (1 nM DHT). Na concentra\u00e7\u00e3o fisiol\u00f3gica, a resposta foi \n\ninferior a 40% para todas as altera\u00e7\u00f5es acima. Uma baixa capacidade de transativa\u00e7\u00e3o do \n\ngene rep\u00f3rter, inferior a 50% quando comparado com o wt, \u00e9 observada em ensaios \n\nrealizados com AR mutante em pacientes com diferentes graus da forma PAIS, assim os \n\ndados obtidos estabelecem uma boa correla\u00e7\u00e3o com o diagn\u00f3stico cl\u00ednico (Werner et al., \n\n2008, Jaaskelainen et al., 2006). No entanto, estas muta\u00e7\u00f5es influenciam a intera\u00e7\u00e3o N/C de \n\nformas diferentes e respondem \u00e0s concentra\u00e7\u00f5es crescentes de DHT tamb\u00e9m de formas \n\ndistintas. Essa diferen\u00e7a pode ser relacionada \u00e0s posi\u00e7\u00f5es que ocupam na estrutura. \n\nEnquanto o res\u00edduo Ser759 encontra-se no sulco de liga\u00e7\u00e3o ao ligante, o res\u00edduo Ile898 \n\nocupa uma regi\u00e3o respons\u00e1vel por intera\u00e7\u00f5es prote\u00edna-prote\u00edna (anexo 1). Essas diferen\u00e7as \n\npodem se refletir na resposta ao tratamento com andr\u00f3genos a que os pacientes geralmente \n\ns\u00e3o submetidos.  \n\nPara as muta\u00e7\u00f5es associadas ao fen\u00f3tipo CAIS, as altera\u00e7\u00f5es p.Leu768Val e \n\np.Pro904Arg apresentaram uma resposta baixa \u00e0 luciferase em concentra\u00e7\u00e3o fisiol\u00f3gica (1 \n\nnM  DHT) no ensaio com o cDNA completo do AR. A altera\u00e7\u00e3o p.Leu768Val anulou a \n\nfun\u00e7\u00e3o do AR, entretanto, a altera\u00e7\u00e3o p.Pro904Arg apresentou 30% de ativa\u00e7\u00e3o do receptor, \n\n\n\n69 \n \n\nresultado que considerado isoladamente poderia associ\u00e1-la ao fen\u00f3tipo PAIS. Entretanto, a \n\nresposta da intera\u00e7\u00e3o N/C terminal da Arg904, assim como a Val768 foi praticamente \n\nabolida, prejudicando desta forma a capacidade de ativa\u00e7\u00e3o transcricional do AR, embora \n\npara a Arg904 esta intera\u00e7\u00e3o se recupere parcialmente atingindo 30-40% da capacidade \n\ntranscricional em concentra\u00e7\u00f5es altas de DHT. A altera\u00e7\u00e3o p.Pro904Arg est\u00e1 localizada na \n\nextremidade da h\u00e9lice 12 que em conjunto com h\u00e9lice 3 e h\u00e9lice 4, comp\u00f5e o subdom\u00ednio \n\nAF2 (anexo 1). Esta altera\u00e7\u00e3o mostrou uma baixa resposta \u00e0 luciferase em todas as \n\nconcentra\u00e7\u00f5es hormonais. V\u00e1rias muta\u00e7\u00f5es relacionadas ao fen\u00f3tipo CAIS t\u00eam sido \n\ndescritas no res\u00edduo 904, como exemplo, as altera\u00e7\u00f5es p.Pro904His e  p.Pro904Ser (Melo et \n\nal., 2003; Werner et al., 2006) indicando que este res\u00edduo seja realmente importante para a \n\nmanuten\u00e7\u00e3o da fun\u00e7\u00e3o do AR. Para a muta\u00e7\u00e3o p.Leu768Val encontrada em um paciente \n\ncom CAIS mostra apenas atividade transcricional em concentra\u00e7\u00f5es hormonais supra-\n\nfisiol\u00f3gicas. Em concentra\u00e7\u00f5es baixas ou fisiol\u00f3gicas, a atividade foi completamente \n\nabolida. O res\u00edduo Leu768 apresenta-se conservado entre outros receptores nucleares, desta \n\nforma, altera\u00e7\u00f5es nessa regi\u00e3o resulta em preju\u00edzo na liga\u00e7\u00e3o com o ligante, como \n\nobservado nas an\u00e1lises funcionais, al\u00e9m de comprometer as intera\u00e7\u00f5es com cofatores da \n\ntranscri\u00e7\u00e3o (Sack et al., 2001). Outras altera\u00e7\u00f5es no res\u00edduo Leu768 foram descritos \n\nassociados ao fen\u00f3tipo PAIS e CAIS (Boehmer, 2001; Ahmed et al., 2000). \n\nAinda relacionadas ao fen\u00f3tipo CAIS, descrevemos a combina\u00e7\u00e3o de altera\u00e7\u00f5es \n\np.Gln798Glu+p.Cys806Phe. Estas muta\u00e7\u00f5es foram encontradas no exon 6 em um paciente \n\ncom CAIS. Para o completo entendimento da contribui\u00e7\u00e3o de cada muta\u00e7\u00e3o para o fen\u00f3tipo \n\nda paciente, estudamos as muta\u00e7\u00f5es primeiro separadamente e depois em conjunto. A \n\naltera\u00e7\u00e3o p.Gln798Glu, apresentou padr\u00e3o de transativa\u00e7\u00e3o compat\u00edvel com MAIS em \n\ntodas as concentra\u00e7\u00f5es hormonais, tanto no ensaio de transativa\u00e7\u00e3o do AR quanto nas \n\nintera\u00e7\u00f5es N/C terminais. A muta\u00e7\u00e3o p.Gln798Glu foi anteriormente investigada in vitro, e \n\nfoi associada com PAIS (Hughes, 2008). Al\u00e9m disso, muta\u00e7\u00f5es no res\u00edduo Gln798 foram \n\ndescritas associados com MAIS, PAIS e c\u00e2ncer da pr\u00f3stata (Hughes et al., 2012). Sua \n\nlocaliza\u00e7\u00e3o perif\u00e9rica contribui para que mudan\u00e7as nesse res\u00edduo n\u00e3o causem grande \n\nimpacto na fun\u00e7\u00e3o proteica (anexo 1). Quando os receptores com as altera\u00e7\u00f5es \n\np.Cys806Phe e p.Gln798Glu+p.Cys806Phe foram expostos a concentra\u00e7\u00f5es fisiol\u00f3gicas de \n\nDHT, as respostas foram aproximadamente 30% e&lt;10%, respectivamente, no experimento \n\n\n\n70 \n \n\ncom o cDNA completo, sendo que para o experimento de intera\u00e7\u00e3o N/C as atividades para \n\na mesma concentra\u00e7\u00e3o de DHT foram menores ainda para cada muta\u00e7\u00e3o. No entanto, a \n\npartir de 10 nM de DHT, houve uma resposta aumentada \u00e0 luciferase, principalmente no \n\nexperimento de intera\u00e7\u00e3o N/C terminal onde a resposta superou a do controle. A \n\ncombina\u00e7\u00e3o entre as muta\u00e7\u00f5es p.Gln798Glu+p.Cys806Phe foi encontrada em um paciente \n\ncom CAIS. Os resultados de transativa\u00e7\u00e3o para a combina\u00e7\u00e3o p.Gln798Glu+p.Cys806Phe \n\napresentou um preju\u00edzo maior na transativa\u00e7\u00e3o, quando comparada com as altera\u00e7\u00f5es \n\nestudadas separadamente. Esse resultado mostra que a combina\u00e7\u00e3o das duas altera\u00e7\u00f5es \n\npromove um efeito aditivo ou sin\u00e9rgico diminuindo ainda mais a atividade funcional do AR \n\nmutante em concentra\u00e7\u00f5es fisiol\u00f3gicas de DHT, embora o aumento de atividade em \n\nconcentra\u00e7\u00f5es maiores tenha sido tamb\u00e9m observado. Este padr\u00e3o \u00e9 conhecido, mas ainda \n\npouco explicado na literatura (Werner et al., 2008; Wong et al., 2008; Perpina et al., 2007). \n\nAlguns autores especulam a possibilidade desta alta resposta estar associada a uma \n\ndisfun\u00e7\u00e3o no recrutamento de co-reguladores da transcri\u00e7\u00e3o, podendo haver um aumento na \n\ntransativa\u00e7\u00e3o. Perpina e colaboradores em 2007 descrevem em seu trabalho uma altera\u00e7\u00e3o \n\nque apresentou o mesmo padr\u00e3o de resposta \u00e0 luciferase, como o aqui mostrado. Segundo \n\nos autores, a altera\u00e7\u00e3o p.Arg840Cys apresentou uma alta resposta \u00e0 luciferase quando \n\nexposto a altas concentra\u00e7\u00f5es de diferentes andr\u00f3genos. Este efeito an\u00f4malo pode estar \n\nassociado a altera\u00e7\u00f5es no mecanismo de recrutamento de cofatores, levando em \n\nconsidera\u00e7\u00e3o a importante regi\u00e3o que esta altera\u00e7\u00e3o se encontra, a regi\u00e3o AF-2 da prote\u00edna \n\nAR. O mesmo resultado foi observado por Wong e colaboradores (2008), para a altera\u00e7\u00e3o \n\np.Phe826Leu (Wong et al., 2008). O subdom\u00ednio AF-2 \u00e9 conhecido entre os receptores \n\nnucleares pela sua conserva\u00e7\u00e3o (Berrevoets et al., 1998) e por apresentar fundamental \n\nimport\u00e2ncia no recrutamento e liga\u00e7\u00e3o de cofatores. Altera\u00e7\u00f5es encontradas neste \n\nsubdom\u00ednio podem aumentar a intera\u00e7\u00e3o entre AF-2 e o dom\u00ednio N-terminal da prote\u00edna \n\nAR, levando a uma capacidade de transativa\u00e7\u00e3o aumentada (Szafran et al., 2009). \n\nA muta\u00e7\u00e3o p.Leu830Phe descrita acima tamb\u00e9m apresentou efeito semelhante e, \n\nacima de 10 nM de DHT, a resposta \u00e0 luciferase foi bastante elevada. O res\u00edduo Leu830 \n\nmostra-se importante para a fun\u00e7\u00e3o do AR visto que, al\u00e9m da muta\u00e7\u00e3o aqui descrita, foi \n\nalvo de outra muta\u00e7\u00e3o associada ao fen\u00f3tipo CAIS (Chaves et al., 2001). A gravidade dos \n\nfen\u00f3tipos dos pacientes com altera\u00e7\u00f5es neste amino\u00e1cido explica-se pela importante regi\u00e3o \n\n\n\n71 \n \n\nque elas se encontram, sendo esta a h\u00e9lice 9 formada pelos amino\u00e1cidos 825 ao 847. O \n\ndom\u00ednio LBD da prote\u00edna AR apresenta duas regi\u00f5es fundamentais: a primeira \u00e9 o \n\nsubdom\u00ednio AF2 que compreende os amino\u00e1cidos 892 ao 896, como descrito acima, e a \n\nsegunda regi\u00e3o \u00e9 conhecido como subdom\u00ednio BF3. Altera\u00e7\u00f5es nestas regi\u00f5es est\u00e3o \n\ndiretamente associadas ao c\u00e2ncer de pr\u00f3stata e AIS (Perpina et al., 2007).  \n\nJ\u00e1 no artigo 3, realizamos a an\u00e1lise funcional da prote\u00edna AR com a muta\u00e7\u00e3o \n\np.Pro695Ser. O paciente que apresenta esta muta\u00e7\u00e3o foi encaminhado por ginecomastia. Na \n\nan\u00e1lise por sequenciamento autom\u00e1tico do gene AR, foi verificado a altera\u00e7\u00e3o p.Pro695Ser, \n\nprimeiramente descrita neste trabalho. A fertilidade deste paciente foi confirmada atrav\u00e9s \n\nda an\u00e1lise da viabilidade dos espermatoz\u00f3ides no espermograma. Os resultados obtidos na \n\nan\u00e1lise funcional da altera\u00e7\u00e3o p.Pro695Ser est\u00e1 de acordo com o fen\u00f3tipo MAIS. Sua \n\nlocaliza\u00e7\u00e3o perif\u00e9rica na estrutura proteica, \u00e0 semelhan\u00e7a do res\u00edduo Gln798 citado acima, \n\nindica um baixo impacto na atividade do AR (anexo 1). Tanto a transativa\u00e7\u00e3o da prote\u00edna \n\nAR completa mutante com p.Pro695Ser quanto a an\u00e1lise das intera\u00e7\u00f5es N/C terminais n\u00e3o \n\nrevelaram redu\u00e7\u00f5es significativas em concentra\u00e7\u00f5es fisiol\u00f3gicas de horm\u00f4nio, quando \n\ncomparadas com a prote\u00edna selvagem na mesma concentra\u00e7\u00e3o hormonal. Uma dr\u00e1stica \n\nredu\u00e7\u00e3o na transativa\u00e7\u00e3o foi observada em baixas concentra\u00e7\u00f5es hormonais, o que pode \n\nexplicar a manifesta\u00e7\u00e3o da ginecomastia. A a\u00e7\u00e3o da testosterona pode estar prejudicada \n\ndevido \u00e0 baixa concentra\u00e7\u00e3o perif\u00e9rica, n\u00e3o sendo suficiente para ativar o receptor, em \n\ncontrapartida, a a\u00e7\u00e3o gonadal preserva a fertilidade. \n\n  Na literatura, existem poucos casos de pacientes com AIS e fertilidade preservada. \n\nAs an\u00e1lises funcionais destes casos s\u00e3o de extrema import\u00e2ncia, uma vez que a atividade do \n\nAR pode ser recuperada em concentra\u00e7\u00f5es altas de horm\u00f4nio. Esses dados colaboram para \n\no desenvolvimento de estrat\u00e9gia medicamentosa para pacientes portadores de MAIS. \n\nA s\u00edndrome de insensibilidade androg\u00eanica \u00e9 conhecida como uma disfun\u00e7\u00e3o na \n\nprote\u00edna AR, que pode ser associado com muta\u00e7\u00f5es no gene de AR ou por mecanismos \n\nainda desconhecidos (Hiort et al., 2000; Hughes, 2008). O sequenciamento completo do \n\ngene AR tem sido uma pe\u00e7a fundamental no grande n\u00famero de muta\u00e7\u00f5es descritas neste \n\ngene. Isso favorece primeiramente o esclarecimento do fen\u00f3tipo do indiv\u00edduo, direciona o \n\nestudo funcional, de modo a analisar o efeito de muta\u00e7\u00f5es nos diferentes dom\u00ednios da \n\nprote\u00edna AR al\u00e9m de elucidar o mecanismo molecular do receptor de andr\u00f3genos.  \n\n\n\n72 \n \n\n7. Conclus\u00f5es: \n\n \n\n\u2022 A muta\u00e7\u00e3o AR_Leu830Phe \n\n\u2022 Est\u00e1 localizada pr\u00f3xima a AF-2 e BF-3; \n\n\u2022 Foi associada aos graus 5 e 6 do fen\u00f3tipo PAIS em duas gera\u00e7\u00f5es de uma fam\u00edlia \n\nBrasileira; \n\n\u2022 Foi descrita pela primeira vez na literatura; \n\n\u2022 A an\u00e1lise in silico da prote\u00edna AR mostrou altera\u00e7\u00f5es entrem o res\u00edduo normal e \n\nmutante. \n\n\u2022 As muta\u00e7\u00f5es p.Ser759Tre, p.Leu830Phe e p.Ile898Phe apresentaram resultados funcionais \n\ncompat\u00edveis com o fen\u00f3tipo PAIS;  \n\n\u2022 As muta\u00e7\u00f5es p.Leu768Val, p.Cys806Phe e p.Pro904Arg: \n\n\u2022 Apresentaram baixo padr\u00e3o de express\u00e3o do gene rep\u00f3rter; \n\n\u2022 Resposta baixa ou alterada nas intera\u00e7\u00f5es N/C terminais; \n\n\u2022 Dados compat\u00edveis com o fen\u00f3tipo CAIS. \n\n\u2022 As muta\u00e7\u00e3o AR_p.Gln798Glu+p.Cys806Phe \n\n\u2022 Apresentou efeito sin\u00e9rgico na transativa\u00e7\u00e3o da prote\u00edna AR mutante. \n\n\u2022 As altera\u00e7\u00f5es p.Leu830Phe e p.Cys806Phe apresentaram efeitos ativadores de fun\u00e7\u00e3o \n\ntranscricional em concentra\u00e7\u00f5es supra-fisiol\u00f3gicas de horm\u00f4nio. \n\n\u2022 A muta\u00e7\u00e3o AR_Pro695Ser foi descrita pela primeira vez na literatura; \n\n\u2022 Altas doses hormonais podem recuperar a atividade do receptor; \n\n\u2022 Atividade transcricional compat\u00edvel com o fen\u00f3tipo MAIS. \n\n\u2022 A an\u00e1lise funcional de muta\u00e7\u00f5es pode ajudar a esclarecer os mecanismos moleculares \n\nassociados \u00e0 prote\u00edna AR. \n\n\u2022 O estudo do efeito de AR mutantes pode auxiliar na escolha da terapia apropriada em casos \n\nde MAIS e PAIS. \n\n \n\n \n\n \n\n \n\n \n\n\n\n73 \n \n\n8. Refer\u00eancias bibliogr\u00e1ficas: \n\n \n\nAdachi M., Takayanagi R., Tomura A., Imasaki K., Kato S., Goto K., Yanase T., Ikuyama \n\nS., Nawata H. (2000) Androgen-insensitivity syndrome as a possible coactivator disease. \n\nThe New England Journal of Medicine 343, 856-862. \n\nAhmed S. F., Cheng A., Dovey L., Hawkins J. R., Martin H., Rowland J., Shimura N. \n\n(2000) Phenotypic features, androgen receptor binding, and mutational analysis in 278 \n\nclinical cases reported as androgen insensitivity syndrome. The Journal of Clinical \n\nEndocrinology and Metabolism, 85(2), 658\u201365.  \n\nBeleza-Meirelles A., Barbaro M., Wedell A., T\u00f6h\u00f6nen V., Nordenskj\u00f6ld A. (2007) Studies \n\nof a co-chaperone of the androgen receptor, FKBP52, as candidate for hypospadias. \n\nReproductive Biology and Endocrinology 5:8. \n\nBerrevoets C. A., Doesburg P., Steketee K., Trapman J., Brinkmann A. O. (1998) \n\nFunctional Interactions of the AF-2 Activation Domain Core Region of the Human \n\nAndrogen Receptor with the Amino-Terminal Domain and with the Transcriptional \n\nCoactivator TIF2 (Transcriptional Intermediary Factor 2), Endocrinology, D., &amp; \n\nReproduction, C. A. B.1172\u20131183. \n\nBoehmer A. L. M., Bru H., Assendelft C., Otten B. J., Verleun-Moijiman M. C. T., \n\nNiermeijer M. F., Brunner H. G., Rouwe\u00b4 C. W., Waelkens J. J., Oostdijk W., Kleijer W. J., \n\nKwast T. H., Vroede M. A., Drop S. L. S. (2001) Genotype versus phenotype in families \n\nwith androgen insensitivity syndrome. Journal of Clinical Endocrinology and Metabolism \n\n86:4151\u20134160. \n\n \n\nBrinkmann A. O. (2011) Androgen action: methods and protocols. Springer \n\nprotocols; Methods in molecular biology, 776. \n\n \n\nhttp://www.worldcat.org/search?qt=hotseries&amp;q=se%3A%22Springer+protocols%22\nhttp://www.worldcat.org/search?qt=hotseries&amp;q=se%3A%22Springer+protocols%22\nhttp://www.worldcat.org/search?qt=hotseries&amp;q=se%3A%22Methods+in+molecular+biology%22\n\n\n74 \n \n\nBuz\u00f3n V., Carb\u00f3 L. R., Estruch S. B., Fletterick R. J. Est\u00e9banez-Perpi\u00f1\u00e1, E. (2012) A \n\nconserved surface on the ligand binding domain of nuclear receptors for allosteric control. \n\nMolecular and cellular endocrinology, 348(2), 394\u2013402. \n\nChang C. S., Kokontis J., Liao S. T. (1988) Structural analysis of complementary DNA and \n\namino acid sequences of human and rat androgen receptors. Proceedings of the National \n\nAcademy of Sciences, 85:7211\u20135.  \n\n \n\nChaves B. et al.,(2001) Eight novel mutations of androgen receptor gene in patients with \n\nandrogen insensitivity syndrome. Journal of Human Genetics, 46:560-565. \n\n \n\nChen H., Yong W., Hind T. D., Yang Z., Zhou Y., Sanchez E. R., Shou W. (2010) Fkbp52 \n\nRegulates Androgen Receptor Transactivation Activity and Male Urethra Morphogenesis. \n\nThe Journal of Biological Chemistry, 285:36. \n\n \n\nCheung-Flynn J., Prapapanich V., Cox M. B., Riggs D. L., Suarez-Quian C., Smith D. F. \n\n(2005) Physiological Role for the Cochaperone FKBP52 in Androgen Receptor Signaling. \n\nMolecular Endocrinology, 19:1654\u20131666. \n\n \n\nClaessens F., Denayer S., Van Tilborgh N., Kerkofs S., Helsen C., Haelens A. (2008) \n\nDiverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nuclear \n\nReceptor, 6: e008. \n\nClinckemalie L., Vanderschueren D., Boonen S., Claessens F. (2012) The hinge region in \n\nandrogen receptor control. Molecular and Cellular Endocrinology, 358(1), 1\u20138.  \n\nCox M. B., Riggs D. L., Hessling M., Schumacher F., Buchner J., Smith D. F. (2007) \n\nFK506 Binding Protein 52 Phosphorylation: A Potential Mechanism for Regulating Steroid \n\nHormone Receptor Activity. Molecular Endocrinology, 21:2956\u20132967. \n\n \n\nFerlin A., Vinanzi C., Garolla A., Selice R., Zuccarello D., Cazzadore C., Foresta C. (2006) \n\nhttp://www.ncbi.nlm.nih.gov/pmc/issues/189655/\n\n\n75 \n \n\nMale infertility and androgen receptor gene mutations: clinical features and identification \n\nof seven novel mutations. Clinical Endocrinology, 65:606-10. \n\n \n\nMorris J. M. (1953) The syndrome of testicular feminization in male \n\npseudohermaphoditism. American Journal of Obstetrics and Gynecology, 65:1192-1211.  \n\nGalani A., Kitsiou-Tzeli S., Sofokleous C., Kanavakis E, Kalpini-Mavrou A (2008) \n\nAndrogen insensitivity syndrome: clinical features and molecular defects. Hormones, \n\n7:217-29. \n\nGhali S. A., Gottlieb B., Lumbroso R., Beitel L. K., Elhaji Y., Wu J., Pinsky L., Trifiro M. \n\nA. (2003) The Use of Androgen Receptor Amino/Carboxyl-Terminal Interaction Assays to \n\nInvestigate Androgen Receptor Gene Mutations in Subjects with Varying Degrees of \n\nAndrogen Insensitivity. Journal of Clinical Endocrinology &amp; Metabolism, 88:2185\u2013 2193. \n\nGirardin C. M., Deal C., Lemyre E., Paquette J., Lumbroso R., Beitel L. K., Trifiro M. A., \n\nVan Vliet G. (2009) Molecular studies of a patient with complete androgen insensitivity \n\nand a 47,XXY karyotype. Journal of Pediatrics, 155:439-43. \n\nGiwercman L., Nikoshkov A., Lindstenk K., Bystron B., Pousette A., Knudtzon J., Alm J., \n\nWedell A. (2000) Response to treatment in patients with partial androgen insensitivity due \n\nto mutations in the DNA-binding domain of the androgen receptor. Hormone Research, \n\n53:83-8. \n\n \n\nGottlieb B., Beitel L. K., Nadaraj A., Paliouras M., Trifiro M. (2012) The androgen \n\nreceptor gene mutations database: 2012 update\n. \n\nArticle first published online: 13 MAR \n\n2012.  \n\n \n\nHeemers H. V., Tindall D. J. (2007) Androgen Receptor (AR) Coregulators: A Diversity of \n\nFunctions Converging on and Regulating the AR Transcriptional Complex. Endocrine \n\nReviews, 28:778\u2013808. \n\n  \n\n\n\n76 \n \n\nHelsen C., Kerkhofs S., Clinckemalie L., Spans L., Laurent M., Boonen S., Claessens F. \n\n(2012) Structural basis for nuclear hormone receptor DNA binding. Molecular and cellular \n\nendocrinology, 348(2), 411\u20137.  \n\n \n\nHiort O., Holterhus P. M., Horter T., Schulze W., Kremke B., Bals-Pratsch M., Sinnecker \n\nG. H., Kruse K. (2000) Significance of mutations in the androgen receptor gene in males \n\nwith idiopathic infertility. Journal of Clinical Endocrinology &amp; Metabolism, 85:2810-5. \n\nHughes I. A. (2008) Disorders of sex development: a new definition and classification. Best \n\nPractice &amp; Research Clinical Endocrinology &amp; Metabolism, 22(1), 119\u201334.  \n\nHughes I. A., Deeb A. (2006) Androgen resistance. Best Practice &amp; Research Clinical \n\nEndocrinology &amp; Metabolism, 20, 577\u2013598. \n\n \n\nHughes I. A. (2001) Diversity in developmental actions of androgens. Clinical \n\nendocrinology, 54, 707\u20138.  \n\nJ\u00e4\u00e4skel\u00e4inen J., Deeb A., Schwabe J. W., Mongan N. P., Martin H., Hughes, I. A. (2000) \n\nHuman androgen receptor gene ligand-binding-domain mutations leading to disrupted \n\ninteraction between the N- and C-terminal domains. Journal of Molecular Endocrinology, \n\n14:1187-97. \n\nK\u00f6hler B., Lumbroso S., Leger J., Audran F., Sarret Grau E., Kurtz F., Pinto G., Salerno \n\nM., Semitcheva T., Czernichow P., Sultan C. (2005) Androgen Insensitivity Syndrome \n\nSomatic Mosaicism of the Androgen Receptor in Seven Families and Consequences for \n\nSex Assignment and Genetic Counseling. The Journal of Clinical Endocrinology &amp; \n\nMetabolism, 90:106-111. \n\n \n\nLarrea F., Benavides G., Scaglia H., Kofman-Alfaro S., Ferrusca E., Medina M. (1978) \n\nGynecomastia as a familial incomplete male pseudohermaphroditism type 1: a limited \n\nandrogen resistance syndrome. The Journal of Clinical Endocrinology &amp; Metabolism, \n\n46:961\u201370.  \n\n\n\n77 \n \n\n \n\nLubahn D. B., Joseph D. R., Sullivan P. M., Willad H. F., French F. S., Wilson E. M. \n\n(1988) Cloning of  Human Androgen Receptor Complementary DNA and Localization to \n\nthe X Chromosome. Science 240:327-330. \n\n \n\nMaciel-Guerra A. T., Guerra-J\u00fanior G. (2002) Menino ou menina? Os dist\u00farbios da \n\ndiferencia\u00e7\u00e3o do sexo. S\u00e3o Paulo: Manole Editora Ltda. \n\n \n\nMelo K. F. S., Mendon\u00e7a B. B., Billerbeck A. E. C., Costa E. M. F., Latronico A. C., \n\nArnhold I. J. P. (2005) S\u00edndrome de Insensibilidade aos Andr\u00f3genos: An\u00e1lise Cl\u00ednica, \n\nHormonal e Molecular de 33 Casos. Arquivos Brasileiros de Endocrinologia e \n\nMetabologia, 49:1. \n\n \n\nMeehan K. L., Sadar M. D. (2003) Androgens and androgen receptor in prostate and \n\novarian malignancies. Frontiers in Bioscirnce, 8:780\u2013800. \n\n  \n\nNitsche E. M., Hiort O. (2000) The Molecular Basis of Androgen Insensitivity. Hormone \n\nResearch, 54:327\u2013333. \n\n \n\nPerpi\u00f1\u00e1 E. E., Arnold L. A., Nguyen P., Rodrigues E. D., Mar E., Bateman R., Pallai P., \n\nShokat K. M., Baxter J. D., Guy R. K., Webb P., Fletterick R. J. (2007) A surface onthe \n\nandrogen receptor that allosterically regulates coactivator binding. Proceedings of National \n\nAcademy of Science, 104:16074-16079. \n\n \n\nPetroli R. J., Maciel-Guerra A. T., Soardi F. C., Leme de Calais F., Guerra-Junior G., Mello \n\nM. P. (2011) Severe forms of partial androgen insensitivity syndrome due to p.L830F novel \n\nmutation in androgen receptor gene in a Brazilian family. BMC Research Notes, 4:173. \n\n \n\nQuigley C. A., De Bellis A., Marschke K. B., Awady M. K., Wilson E. M., French F. S. \n\n(1995) Androgen receptor defects: historical, clinical, and molecular perspectives. \n\nEndocrine, 16:271\u2013321. \n\n\n\n78 \n \n\n \n\nRajender S., Singh L., Thangaraj K. (2007) L859F mutation in androgen receptor gene \n\nresults incomplete loss of androgen binding to the receptor. Journal of Andrology, 28: 772-\n\n776. \n\n \n\nRong H. L., Suzuki N., Imai A. (2010) A double nucleotide insertion-induced frame-shift \n\nmutation of the androgen receptor gene in a familial complete androgen insensitivity \n\nsyndrome. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 148: \n\n53-55. \n\n \n\nSunnotel O., Hiripi L., Lagan K., McDaid J. R., De Le\u00f3n J. M., Miyagawa Y., Crowe1 H., \n\nKaluskar S., Ward M., Scullion C., Campbell A., Downes C. S., Hirst D., Barton D.,  \n\nMocanu E., Tsujimura A., Cox M. B., Robson T., Walsh C. P. (2010) Alterations in the \n\nsteroid hormone receptor  co-chaperone FKBPL are associated with male infertility: a case-\n\ncontrol study. Reproductive Biology and Endocrinology, 8:22. \n\n \n\nSzafran A. T., Hartig S., Sun H., Uray I. P., Szwarc M., Shen Y., Mediwala S. N., et al. \n\n(2009) Androgen receptor mutations associated with androgen insensitivity syndrome: a \n\nhigh content analysis approach leading to personalized medicine. PLOS ONE, 4(12), \n\ne8179.  \n\n \n\nTanner T., Denayer S., Geverts B., Van Tilborg, N., Kerkhofs S., Helsen C., Spans L., \n\nDubois V., Houtsmuller A. B., Claessens F., Haelens A. (2010) A 629RKLKK633 motif in \n\nthe hinge region controls the androgen receptor at multiple levels. Cellular and Molecular \n\nLife Sciences, 67, 1919\u20131927. \n\n \n\nTilley W. D., Marcelli M., Wilson J. D., McPhaul M. J. (1989) Characterization and \n\nexpression of a cDNA encoding the human androgen receptor. Proceedings of the National \n\nAcademy of Sciences of the United States of America, 86(1), 327\u201331.  \n\n \n\n\n\n79 \n \n\nTrapman J., Klaassen P., Kuiper G. G., van der Korput J. A., Faber P. W., van Rooij H. \n\nC., et al. (1988) Cloning, structure and expression of a cDNA encoding the \n\nhuman androgen receptor. Biochemical Biophysical Research Communication, 153:241-8. \n\n \n\nTufan A. C., Satiroglu-Tufan N. L., Aydinuraz B., Satiroglu M. H., Aydos K., Bagci H. \n\n(2005) No association of the CAG repeat length in exon 1 of the androgen receptor gene \n\nwith idiopathic infertility in Turkish men: implications and literature review. The Tohoku \n\njournal of experimental medicine, 206(2), 105\u201315.  \n\nWerner R., Zhan J., Gesing J., Struve D., Hiort, O. (2008) In-vitro characterization of \n\nandrogen receptor mutations associated with complete androgen insensitivity syndrome \n\nreveals distinct functional deficits. Sexual development?: genetics, molecular biology, \n\nevolution, endocrinology, embryology, and pathology of sex determination and \n\ndifferentiation, 2(2), 73\u201383.  \n\n \n\nWong H. Y., Hoogerbrugge J. W., Pang K. L., van Leeuwen M., van Royen M. E., Molier, \n\nM., Brinkmann A. O. (2008) A novel mutation F826L in the human androgen receptor in \n\npartial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain \n\ninteraction and TIF2 co-activation. Molecular and cellular endocrinology, 292(1-2), 69\u201378.  \n\nWu X., Zhou Q., Mao J., Lu S., Nie M. (2010) Mutational analysis of androgen receptor \n\ngene in four Chinese patients with male pseudohermaphroditism. Fertility and Sterility, \n\n93(6):2076. \n\n \n\nYong E. L., Tut T. G., Ghadessy F. J., Prins G., Ratnam S. S. (1998) Partial androgen \n\ninsensitivity and correlations with the predicted three dimensional structure of the androgen \n\nreceptor ligand-binding domain. Molecular and cellular endocrinology, 137(1), 41\u201350. \n\n \n\nYong E. L., Loy C. J., Sim K. S. (2003) Androgen receptor gene and male infertility. \n\nHuman Reproduction, 9:1-7. \n\n \n\n \n\n\n\n80 \n \n\n9. Anexos \n\n9.1 Anexo 1: An\u00e1lise estrutural das prote\u00ednas AR mutantes \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido 759.  \n\nEm A, o res\u00edduo selvagem Ser759 realiza uma ponte de hidrog\u00eanio com o res\u00edduo Ser725 e \n\numa intera\u00e7\u00e3o hidrof\u00f3bica com o res\u00edduo Phe764. Em B, res\u00edduo mutante Tre759 mant\u00e9m \n\nas liga\u00e7\u00f5es feitas pelo res\u00edduo normal e cria mais tr\u00eas intera\u00e7\u00f5es hidrof\u00f3bicas com os \n\nres\u00edduos Arg760 e Phe764. Em C, estrutura simplificada do dom\u00ednio de liga\u00e7\u00e3o ao \n\nhorm\u00f4nio da prote\u00edna AR, evidenciando o amino\u00e1cido Serina 759, localizado entre as \n\nh\u00e9lices 5 e 6. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido 898. \n\nEm A, o res\u00edduo selvagem Ile898. A isoleucina na posi\u00e7\u00e3o 898 apresenta 3 pontes de \n\nSer759 \n\nA \n\nB C \n\nIle898 \nA \n\nB c \n\n\n\n81 \n \n\nhidrog\u00eanio com os res\u00edduos: Val902, Met893 e Gln900  e 4 intera\u00e7\u00f5es hidrof\u00f3bicas com os \n\nres\u00edduos: Gln900, Met712 e Trp740. Em B, res\u00edduo mutante Phe898. A fenilalanina na \n\nposi\u00e7\u00e3o 898 mant\u00e9m as  pontes de hidrog\u00eanio com Val902 e Met893 e cria intera\u00e7\u00f5es com \n\nos res\u00edduos Val902, Gln900, Trp740 e Gln737. O n\u00famero de intera\u00e7\u00f5es hidrof\u00f3bicas no \n\nres\u00edduo mutante aumenta para 12 quando comparado com res\u00edduo normal. Em C, estrutura \n\nsimplificada do dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio da prote\u00edna AR, evidenciando o \n\namino\u00e1cido Isoleucina 898, localizado na h\u00e9lice 11. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido 768. \n\nEm A, o res\u00edduo selvagem Leu768 faz duas pontes de hidrog\u00eanio com a Ala765 e quatro \n\nintera\u00e7\u00f5es hidrof\u00f3bicas com Phe770 e Leu702. Em B, o res\u00edduo mutante Val768 mant\u00e9m \n\nsomente o contato com o amino\u00e1cido Ala765 e cria mais tr\u00eas novos contatos com os \n\namino\u00e1cidos Phe764, His689 e Ala687. As intera\u00e7\u00f5es hidrof\u00f3bicas tamb\u00e9m s\u00e3o alteradas, o \n\nres\u00edduo selvagem Leu768 faz quatro intera\u00e7\u00f5es hidrof\u00f3bicas com Phe770 e Leu702 e o \n\nres\u00edduo Val768 fazendo seis intera\u00e7\u00f5es hidrof\u00f3bicas com Phe764, His689 e Ala687. Em C, \n\nestrutura simplificada do dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio da prote\u00edna AR, evidenciando o \n\namino\u00e1cido Leucina 768, localizado entre as h\u00e9lices 5 e 6. \n\n \n\n \n\n \n\n \n\nLeu768Val \n\nA \n\nB C \n\n\n\n82 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido 904. \n\nEm A, o res\u00edduo selvagem Pro904 faz duas pontes de hidrog\u00eanio com os amino\u00e1cidos  \n\nSer908 e Gln902 e tr\u00eas intera\u00e7\u00f5es hidrof\u00f3bicas com o amino\u00e1cido Ser 900. Em B, o res\u00edduo \n\nmutante Arg904, mant\u00e9m a intera\u00e7\u00e3o com os amino\u00e1cidos  Ser908 e Gln902 e cria novos \n\ncontatos com os amino\u00e1cidos  Arg910 e Leu907 e perde a liga\u00e7\u00e3o Ser900 . Duas intera\u00e7\u00f5es \n\nhidrof\u00f3bicas s\u00e3o perdidas no res\u00edduo mutante Arg904. Em C, estrutura simplificada do \n\ndom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio da prote\u00edna AR, evidenciando o amino\u00e1cido Prolina, \n\nlocalizado na h\u00e9lice 12. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPro904 \n\nA \n\nB C \n\nCys806 \n\nA \n\nC B \n\n\n\n83 \n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido 806. \n\nEm A, o res\u00edduo selvagem Cys806 O res\u00edduo normal apresenta 3 pontes de hidrog\u00eanio com \n\nos amino\u00e1cidos Leu810, Arg808, Gln802 e Ile841. O res\u00edduo mutante mant\u00e9m as pontes de \n\nhidrog\u00eanio com os res\u00edduos Leu810, Arg808 e Gln802 e cria intera\u00e7\u00f5es hidrof\u00f3bicas com \n\nLeu838, Tyr834, Leu810 e Leu839. Em C, estrutura simplificada do dom\u00ednio de liga\u00e7\u00e3o ao \n\nhorm\u00f4nio da prote\u00edna AR, evidenciando o amino\u00e1cido Ciste\u00edna, localizado na h\u00e9lice 8. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido da \n\nposi\u00e7\u00e3o 798. Em A, o res\u00edduo selvagem Gln798 faz conto com os amino\u00e1cidos Arg855, \n\nGln795 e Phe794. Em B, O res\u00edduo mutante Glu798 perde uma ponte de hidrog\u00eanio feita \n\ncom amino\u00e1cido Arg855 e mant\u00e9m duas pontes de hidrog\u00eanio com o amino\u00e1cido Phe766. \n\nEm C, estrutura simplificada do dom\u00ednio de liga\u00e7\u00e3o ao horm\u00f4nio da prote\u00edna AR, \n\nevidenciando o local da altera\u00e7\u00e3o o amino\u00e1cido Gln798, no loop entre as h\u00e9lices 7 e 8 da \n\nprote\u00edna AR. \n\n \n\n \n\n \n\n \n\n \n\n \n\nGln798 \n\nA \n\nB \n\n\n\n84 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAn\u00e1lise estrutural do dom\u00ednio de liga\u00e7\u00e3o da prote\u00edna AR, evidenciando o amino\u00e1cido da \n\nposi\u00e7\u00e3o 695. Em A, o res\u00edduo selvagem Pro695 e em B, o res\u00edduo mutante Ser695. Ambos \n\nres\u00edduos n\u00e3o estabelecem contatos internos. Em C, estrutura simplificada do dom\u00ednio de \n\nliga\u00e7\u00e3o ao horm\u00f4nio da prote\u00edna AR, evidenciando o local da altera\u00e7\u00e3o p.Pro695Ser no \n\nloop entre as h\u00e9lices 1 e 3 da prote\u00edna AR, uma posi\u00e7\u00e3o superficial externa. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPro695 \n\nA \n\nB C \n\n\n\n85 \n \n\n9.2 Anexo II \u2013 Declara\u00e7\u00e3o Bio\u00e9tica e Biosseguran\u00e7a"}]}}}